

STATEMENT

We, ACON Laboratories, Inc., having a registered office at *5850 Oberlin Drive #340, San Diego, CA 92121* authorize SRL Sanmedico having a registered office at *A. Corobceanu street 7A, apt. 9, Chisinău, MD-2012, Moldova*

to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova.

Date: January 3, 2023

Signature:



Qiyi Xie, Md, MPH
Sr. Officer, Regulatory & Clinical Affairs
ACON Laboratories, Inc.
Ph: 858-875-8011
Email: qxie@aconlabs.com

Declaration of Conformity

ACON Laboratories, Incorporated
5850 Oberlin Drive #340
San Diego, CA 92121, USA

**We, the manufacturer, declare under our sole responsibility that the
in vitro diagnostic device:**

Mission[®] Urinalysis Reagent Strips (U031-XX1)

classified as Others in the directive 98/79/EC,

**meets all the provisions of the directive 98/79/EC on *in vitro* diagnostic
medical devices which apply to it**

**The self-declaration is according to Annex III
(excluding Section 6) of the Directive.**

Authorized Representative:
Medical Device Safety Service GmbH
Schiffgraben 41
30175 Hannover, Germany

Signed this 11 day of February, 2020
in San Diego, CA USA



Qiyi Xie, MD, MPH
Senior Staff, Regulatory Affairs & Clinical Affairs
Acon Laboratories, Inc.



Declaration of Conformity

ACON Laboratories, Incorporated
5850 Oberlin Drive, #340
San Diego, CA 92121, USA

**We, the manufacturer, declare under our sole responsibility that the
in vitro diagnostic device:**

Device Name	REF Number	Model Number
Mission® Liquid Urine Control	U021-011	n/a
SPINREACT Liquid Urine Control	U021-013A	n/a
Insight® Liquid Urine Control	U021-015	n/a
Mission® Liquid Diptube Urine Control	U021-071	n/a
Insight® Liquid Diptube Urine Control	U021-075	n/a

classified as Others in the directive 98/79/EC,

**meets all the provisions of the directive 98/79/EC on *in vitro* diagnostic
medical devices which apply to it**

**The self-declaration is according to Annex III
(excluding Section 6) of the Directive.**

Authorized Representative:
Medical Device Safety Service GmbH
Schiffgraben 41
30175 Hannover, Germany

Signed this 22 day of October, 2021
in San Diego, CA, USA



Qiyi Xie, MD, MPH
Senior Staff, Regulatory Affairs & Clinical Affairs
Acon Laboratories, Inc.





Benannt durch/Designated by
Zentralstelle der Länder
für Gesundheitsschutz
bei Arzneimitteln und
Medizinprodukten
www.zlg.de
ZLG-BS-245.10.07



Product Service

EC Certificate

Full Quality Assurance System

Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV excluding (4, 6)
(List A and B and devices for self-testing)

No. V1 104507 0003 Rev. 06

Manufacturer:

ACON Laboratories, Inc.

5850 Oberlin Drive, #340
San Diego CA 92121
USA

**Product Category(ies): Blood glucose measuring systems for self testing
and self-testing devices for clinical chemistry,
hematology and pregnancy and ovulation**

The Certification Body of TÜV SÜD Product Service GmbH declares that the aforementioned manufacturer has implemented a quality assurance system for design, manufacture and final inspection of the respective devices / device families in accordance with IVDD Annex IV. This quality assurance system conforms to the requirements of this Directive and is subject to periodical surveillance. For marketing of List A devices an additional Annex IV (4) certificate is mandatory. All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: [www.tuvsud.com/ps-cert?q=cert:V1 104507 0003 Rev. 06](http://www.tuvsud.com/ps-cert?q=cert:V1_104507_0003_Rev.06)

Report no.:

SH22743EXT01

Valid from:

2022-05-04

Valid until:

2025-05-26

Date,

2022-05-04

Christoph Dicks
Head of Certification/Notified Body



EC Certificate

Full Quality Assurance System

Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV excluding (4, 6)
(List A and B and devices for self-testing)

No. V1 104507 0003 Rev. 06

Model(s):

On Call Plus Blood Glucose Monitoring System,
On Call Plus Blood Glucose Test Strips,
On Call EZ II Blood Glucose Monitoring System,
On Call Advanced Blood Glucose Monitoring System,
On Call Advanced Blood Glucose Test Strips,
On Call Chosen Blood Glucose Test Strips,
On Call Vivid Blood Glucose Monitoring System (OGM-101),
On Call Vivid Blood Glucose Test Strips (OGS-101),
On Call Sharp Blood Glucose Monitoring System (OGM-121),
On Call Sharp Blood Glucose Test Strips (OGS-121)
On Call Plus II Blood Glucose Monitoring System (OGM-171),
On Call Plus II Blood Glucose Test Strips (OGS-171),
On Call Extra Blood Glucose Monitoring System (OGM-191),
On Call Extra Blood Glucose Test Strips (OGS-191),
On Call GK Dual Blood Glucose & Ketone Monitoring System (OGM-161),
On Call Blood Ketone Test Strips (OGS-161),
Urinalysis Reagent Strips (Urine),
UTI Urinary Tract Infection Test Strips,
Cholesterol Monitoring System (CCM-111),
CHOL Total Cholesterol Test Devices (CCS-111),
TRIG Triglycerides Test Devices (CCS-112),
HDL High Density Lipoprotein Test Devices (CCS-113),
3-1 Lipid Panel Test Devices (CCS-114),
Cholesterol CTRL Control Devices,
Cholesterol Monitoring System (CCM-101),
CHOL Total Cholesterol Test Strips (CCS-101),
PT/INR Monitoring System (CCM-151),
PT/INR Test Strips (CCS-151),
Hemoglobin Testing System (CCM-141),
Hemoglobin Test Strips (CCS-141),
hCG Pregnancy Rapid Test Cassette (Urine),
Pregnancy Rapid Test Midstream,
On Call Extra Mobile Blood Glucose Monitoring System (OGM-281),
On Call Sure Blood Glucose Monitoring System (OGM-211),
On Call Sure Sync Blood Glucose Monitoring System (OGM-212),
On Call Sure Blood Glucose Test Strips (OGS-211),
GIMA Blood Glucose Monitoring System,
GIMA Bluetooth Blood Glucose Monitoring System,
GIMA Blood Glucose Test Strips,
On Call GU Dual Blood Glucose & Uric Acid Monitoring



EC Certificate

Full Quality Assurance System

Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV excluding (4, 6)
(List A and B and devices for self-testing)

No. V1 104507 0003 Rev. 06

System (OGM-201),
On Call Blood Uric Acid Test Strips (OGS-201),
LH Ovulation Rapid Test Cassette (Urine),
Ovulation Rapid Test Midstream,
Ovulation & Pregnancy Test Combo Pack,
On Call Extra Voice Blood Glucose Monitoring System
(OGM-291),
Early Detection Pregnancy Test,
Digital Pregnancy Test,
Go-Keto Blood Glucose & Ketone Monitoring System (OGM-
161),
Go-Keto Blood Ketone Test Strips (OGS-161),
Go-Keto Blood Glucose Test Strips,
On Call Extra GM Blood Glucose Monitoring System(OGM-
191),
On Call Extra GM Blood Glucose Test Strips (OGS-191),
On Call Plus GM Blood Glucose Monitoring System,
On Call Plus GM Blood Glucose Test Strips,
Go-Keto Urinalysis Reagent Strips

Facility(ies):

ACON Laboratories, Inc.
5850 Oberlin Drive, #340, San Diego CA 92121, USA

ACON Laboratories, Inc.
10125 Mesa Rim Road, San Diego CA 92121, USA

AZURE Institute, Inc.
10125 Mesa Rim Road, San Diego CA 92121, USA

Acon Laboratories Inc.
Guerrero Negro 9942 Parque Industrial Pacifico IV, 22644 Tijuana
B.C. CP, MEXICO



Certificate

No. Q5 104507 0001 Rev. 03

Holder of Certificate: **ACON Laboratories, Inc.**
5850 Oberlin Drive, #340
San Diego CA 92121
USA

Certification Mark:



Scope of Certificate: **Design and Development, Manufacture and distribution of In Vitro Diagnostic Test Kits and Reagents for the Determination of Infectious Diseases, Clinical Chemistry, Drugs of Abuse, Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose Monitoring System, Lancing Devices and Lancets**

The Certification Body of TÜV SÜD Product Service GmbH certifies that the company mentioned above has established and is maintaining a quality management system, which meets the requirements of the listed standard(s). All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: www.tuvsud.com/ps-cert?q=cert:Q5 104507 0001 Rev. 03

Report No.: SH22743A01

Valid from: 2022-09-15
Valid until: 2025-09-06

Date, 2022-09-15

Christoph Dicks
Head of Certification/Notified Body

Certificate

No. Q5 104507 0001 Rev. 03

Applied Standard(s):

EN ISO 13485:2016
Medical devices - Quality management systems -
Requirements for regulatory purposes
(ISO 13485:2016)
DIN EN ISO 13485:2016

Facility(ies):

ACON Laboratories, Inc.
5850 Oberlin Drive, #340, San Diego CA 92121, USA

Address holder for registration only

ACON Laboratories, Inc.
10125 Mesa Rim Road, San Diego CA 92121, USA

Manufacture and distribution of
In Vitro Diagnostic Test Kits and Reagents for the Determination of
Infectious Diseases, Clinical Chemistry, Drugs of Abuse,
Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose
Monitoring System, Lancing Devices and Lancets

ACON Laboratories, Inc.
6865 Flanders Dr., Suite B, San Diego CA 92121, USA

Storage of
In Vitro Diagnostic Test Kits and Reagents for the Determination of
Infectious Diseases, Clinical Chemistry, Drugs of Abuse,
Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose
Monitoring System, Lancing Devices and Lancets

AZURE Institute, Inc.
10125 Mesa Rim Road, San Diego CA 92121, USA

Design and Development of
In Vitro Diagnostic Test Kits and Reagents for the Determination of
Infectious Diseases, Clinical Chemistry, Drugs of Abuse,
Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose
Monitoring System, Lancing Devices and Lancets

Acon Laboratories Inc.
Guerrero Negro 9942 Parque Industrial Pacifico IV, 22644
Tijuana B.C. CP, MEXICO

Manufacture of
blood glucose test strips, antigen rapid test and IgG/IgM antibody
rapid test for infectious disease.

Mission® Urinalysis Reagent Strips and Urine Analyzers

Obtain reliable and cost-effective results with *Mission®* Urinalysis Reagent Strips and Urine Analyzers!

- *Accurate*
- *Reliable*
- *Convenient*



Global Diagnostics for Local Markets™

Urinalysis Reagent Strips

Simple and Accurate


- Analytical sensitivity better than or comparable to market leaders
- High quality color chart ensures accurate visual reading

Flexible


- Compatible for visual and analyzer reading
- More than 30 different combinations available

Multiple Packaging Options and Long Shelf Life

- Canister Packaging
 - Available in 25, 50, 100 and 150 strips per kit
 - 2 year shelf life for unopened canisters which offers cost savings and convenience for high volume testing
 - 3 month shelf life for strips in opened canisters
- Pouch Packaging *New!*
 - Single-strip Pouch
 - Individually packaged strips with 1, 3, 6 and 20 strips and 1 color chart per kit for OTC or low volume testing
 - Unique packaging maintains 2 year shelf life for all strips in the kit compared to 3 months for remaining strips in an opened canister
 - Multi-strip Pouch
 - Canister Refill Kits with 25 strips/pouch uniquely packaged to save cost for low volume testing and extended shelf life by using the canister for refills




Step 1: Immerse strip into urine



Step 2: Remove excess urine



Step 3: Obtain results by analyzer or visual reading



Catalog No.	No. of Parameters	Type of Strip [♦]		Strips per Canister [◊]	Pouch Packaging [▲]	Reading Method			Analyzer-Read Strips: Standard (S) or Additional (A)	Parameters												
		For Visual Reading	For Analyzer Reading (U120/U500)			Visual	U120	U500		ASC	GLU	BIL	KET	SG	BLO	pH	PRO	URO	NIT	LEU	ALB	CRE
U031-131	13	13C	NA	100 [■]	✓	✓	NA	NA	A	*	*	*	*	*	*	*	*	*	*	*	*	*
U031-111	11	11A		100	✓	✓	✓	✓	S	*	*	*	*	*	*	*	*	*	*	*		
U031-101	10	10U		100	✓	✓	✓	✓	S		*	*	*	*	*	*	*	*	*	*		
		10A				✓	✓	✓	A	*	*	*	*	*	*	*	*	*	*			
		10C				✓	✓	✓	S		*	*	*	*	*	*	*	*	*	*	*	
U031-091	9	9U		100	✓	✓	✓	✓	S		*	*	*	*	*	*	*	*	*			
U031-081	8	8U		100	✓	✓	✓	✓	A		*	*	*	*	*	*	*	*	*	*		
		8N				✓	✓	✓	S		*	*	*	*	*	*	*	*	*	*		
		8S				✓	✓	✓	A		*	*	*	*	*	*	*	*	*	*		
U031-071	7	7N		100	✓	✓	✓	✓	A		*		*		*	*	*	*	*			
U031-061	6	6N	6NE	100	✓	✓	✓	✓	A		*				*	*	*	*	*	*		
		6U	6UE			✓	✓	✓				*		*	*	*	*	*	*			
U031-051	5	5B	5BE	100	✓	✓	✓		A		*		*		*	*	*					
		5N	5NE			✓	✓	✓			*				*	*	*	*	*	*		
		5S	5SE			✓	✓	✓			*			*	*	*	*	*	*	*		
		5U	5UE			✓	✓				*			*	*	*	*	*	*	*		
U031-041	4	4S	4SE	100	✓	✓	✓	✓	A		*			*	*	*	*	*	*			
		4B	4BE			✓	✓				*			*	*	*	*	*	*			
		4K	4KE			✓	✓	✓			*	*	*	*	*	*	*	*	*			
		4G	4GE			✓	✓				*			*	*	*	*	*	*			
		4N	4NE			✓	✓	✓						*	*	*	*	*	*			
		4P	4PE			✓	✓	✓			*			*	*	*	*	*	*			
U031-031	3	3P	3PE	100	✓	✓	✓	✓	A		*				*	*	*	*	*			
		3K	3KE			✓	✓	✓			*	*	*	*	*	*	*	*	*			
		3G	3GE			✓	✓	✓			*	*	*	*	*	*	*	*	*			
		3N	3NE			✓	✓	✓					*	*	*	*	*	*	*			
U031-021	2	2G	2GE	100	✓	✓	✓	✓	A		*				*	*	*	*	*			
		2K	2KE			✓	✓	✓			*	*	*	*	*	*	*	*	*			
		2N	2NE			✓	✓	✓					*	*	*	*	*	*	*			
		2B	2BE			✓	✓	✓			*	*	*	*	*	*	*	*	*			
		2U	2UE			✓	✓	✓						*	*	*	*	*	*			
		2S	2SE			✓	✓	✓					*	*	*	*	*	*	*			
		2C	2CE	100 [■]	✓	✓	✓										*	*				
U031-011	1	1B	1BE	100	✓	✓	✓		A					*	*	*	*	*	*			
		1P	1PE			✓	✓	✓						*	*	*	*	*	*			
		1G	1GE			✓	✓	✓			*	*	*	*	*	*	*	*	*			
		1K	1KE			✓	✓	✓				*	*	*	*	*	*	*				
		1R	1RE			✓	✓	✓				*	*	*	*	*	*	*				

♦ Type of Strip:
 Visual Strip Size
 1-6 Parameters: 5 mm x 80 mm; 7-11 Parameters: 5 mm x 108 mm;
 12-13 Parameters: 5 mm x 121 mm
 U120/U500 Strip Size
 1-11 Parameters: 5 mm x 108 mm;
 "E" means extended strip length for 1-6 Parameters

◊ Also available in canisters of 25, 50 and 150 strips
 ▲ Not available in canisters of 150 strips
 ▲ Single-strip Pouch available in 1, 3, 6 and 20 strip kit
 Canister Refill Kit, with 25 strips per pouch or canister, available in 3-pouch and 1- canister kit, or 4-pouch kit

CE Marked for sale in the European Community
 Cleared for US 510(k)



U120 Urine Analyzer



Accurate

- Up to 120 tests/hour in Continuous Test Option
- Capable of reading 1 strip at a time in Single Test Option
- Test modes include Routine, STAT and QC
- Automatic calibration for accurate results and easy operation

Reliable

- Can read up to 4 Strip combinations with 8, 9, 10, 11 parameters, additional strips with 1-11 parameters available upon request
- Minimal training required

Convenient Operation

- Saves and recalls the last 2,000 results automatically
- Audible beep signals operator to dip strips in urine
- Can print up to 3 copies per test for convenient reviewing and easy record keeping
- Option to print results on sticker paper for quick and simple record management

Easy Data Management

- Includes RS232C port for easy data transfer to an external computer or LIS
- Optional Barcode Reader to record patient ID

Unique Lockout Functions *new!*

- Strip Lockout
 - Prevents using strips of another brand on the U120 Urine Analyzer
 - Requires barcode reader scan or manual entry of the canister code
- User Lockout
 - Eliminates unapproved users from testing
 - Up to 10 lab operators can perform testing, but only the lab administrator can change analyzer settings
- QC Lockout
 - Prevents testing without passing QC
 - QC tests can be performed once every 8 hours, day, week or month
 - Analyzer will alert when to run QC test
 - If QC tests fail, analyzer will switch to STAT mode and list "E" at the end of each test number

Specifications

Feature	Specifications
Analyzer Type	Manual
Methodology	Reflectance Photometry
Detection	Photosensitive Diode
Throughput	Single Test Option: 60 tests/hour Continuous Test Option: 120 tests/hour
Test Modes	Routine, STAT and QC
Lockout Functions	Strip Lockout: Available Upon Request; User/QC Lockout: Included with option to turn ON/OFF
Memory	Last 2,000 results
Strip Incubation Time	1 Minute
Wavelength of Monochromatic LED	525 nm and 635 nm
Standard Strips	8, 9, 10, 11 Parameters (5 mm x 108 mm)
Additional Strips Available	1-11 Parameters (5 mm x 108 mm); see URS Parameters
Total Combinations Per Analyzer	4 Combinations
Analyzer Ports	Standard RS232C Port for Barcode Reader or Data Transfer USB Port for Data Transfer 25 Pin Parallel Port for External Printer
Capabilities	Internal Thermal Printer (included) RS232C Barcode Reader (optional) Optional External Printer (not included) USB or RS232C Data Transfer Cable (optional)
Major Readable Barcodes	Code 128, Code 39, Codabar (NW-7), Interleaved 25, UPC-A, UPC-E, EAN 8, EAN 13
Calibration	Automatic
Available Languages on the Screen	English and additional language(s)
Operating Conditions	0-40°C (32-104°F); ≤ 85% RH
Storage Conditions	-5-50°C (23-122°F); ≤ 90% RH
Power Source	100-240 VAC, 50-60 Hz
Dimensions (L x W x H)	27.2 cm x 26.9 cm x 14.6 cm (10.7" x 10.6" x 5.7")
Display Dimensions (L x W)	10.8 cm x 5.7 cm (4.2" x 2.2")
Weight	2.6 kg (5.7 lbs)

Ordering Information

Product Name	Catalog No.	Components		Kit Box Dimensions (L x W x H) & Weight	Carton Dimensions (L x W x H) & Weight	Number of Kits/Carton
U120 Urine Analyzer	U111-101 [†]	1 Urine Analyzer 1 Strip holder 2 Printer Paper Rolls	2 Fuses (2.0A) 1 Power Cord 1 Quick Start Guide 1 Instruction Manual	42.0 cm x 41.5 cm x 31 cm; 5.0 kg 16.4" x 16.2" x 12.1"; 176.4 oz		1
U120 Urine Analyzer with Barcode Reader	U111-111 [†]	1 Urine Analyzer 1 Strip holder 2 Printer Paper Rolls 1 Barcode Reader (RS232C)	2 Fuses (2.0A) 1 Power Cord 1 Serial Splitter Cable (RS232C) 1 Quick Start Guide 1 Instruction Manual	44.5 cm x 44.5 cm x 40.0 cm; 5.5 kg 17.5" x 17.5" x 15.7"; 194 oz		1
Barcode Reader	U221-111 [†]	1 Barcode Reader (RS232C)	1 Serial Splitter Cable (RS232C)	23.6 cm x 10.8 cm x 7.8 cm; 0.482 kg 9.3" x 4.3" x 3.1"; 17.0 oz	63.0 cm x 37.0 cm x 30.0 cm; 12.0 kg 24.8" x 14.6" x 11.8"; 423.3 oz	22
Printer Paper Rolls	U121-101	4 Printer Paper Rolls	Thermal Paper (0.06 m x 20 m): 200 results/roll Sticker Paper (0.06 m x 9 m): 100 results/roll	12.0 cm x 12.0 cm x 6.5 cm; 0.36 kg 4.7" x 4.7" x 2.6"; 12.7 oz 12.0 cm x 12.0 cm x 6.5 cm; 0.4 kg 4.7" x 4.7" x 2.6"; 14.1 oz	63.0 cm x 37.0 cm x 30.0 cm; 19.4 kg 24.8" x 14.6" x 11.8"; 684.3 oz 63.0 cm x 37.0 cm x 30.0 cm; 21.4 kg 24.8" x 14.6" x 11.8"; 684.3 oz	50
U120 Data Transfer Kit	U221-131 [†]	1 Data Transfer Cable (RS232C)	1 Package Insert	16.0 cm x 13.0 cm x 3.5 cm; 0.147 kg 6.3" x 5.1" x 1.4"; 5.2 oz	25.0 cm x 21.0 cm x 15.0 cm; 1.36 kg 9.8" x 8.3" x 5.9"; 48.0 oz	8

U500 Urine Analyzer



Accurate and Efficient

- Up to 500 tests/hour for medium/large volume sample testing
- Professional accuracy equivalent to market leader
- Automatic strip detection and alignment for better efficiency
- Test modes include Routine, STAT and QC

Easy to Operate

- Large touch screen LCD offers simple menu navigation
- Uniquely designed strip platform/waste tray unit for easy one-step cleaning

Convenient

- Automatic calibration and waste disposal reduce hands-on time
- Can read strips with 8, 9, 10, 11 parameters, additional strips with 1-11 parameters available upon request
- Strip selection of up to 4 combinations for analyzer reading
- Stores up to 2,000 records and automatically flags abnormal results
- Capable of printing results on sticker paper for quick and easy record management

Data Management Capability

- Includes RS232C port for easy data transfer to an external computer or LIS
- Optional Barcode Reader to record patient ID

Unique Lockout Functions Coming Soon!

- Strip Lockout
 - Prevents using strips of another brand on the U500 Urine Analyzer
 - Requires barcode reader scan or manual entry of the canister code
- User Lockout
 - Eliminates unapproved users from testing
 - Up to 10 lab operators can perform testing, but only the lab administrator can change analyzer settings
- QC Lockout
 - Prevents testing without passing QC
 - QC tests can be performed once every 8 hours, day, week or month
 - Analyzer will alert when to run QC test
 - If QC tests fail, analyzer will switch to STAT mode and list "E" at the end of each test number

Specifications

Feature	Specifications
Analyzer Type	Semi-Automatic
Methodology	Reflectance Photometry
Detection	Photosensitive Diode
Throughput	500 tests/hour (Measuring cycle: 7 seconds/test)
Test Modes	Routine, STAT and QC
Lockout Functions	Strip Lockout: Available Upon Request; User/QC Lockout: Included with option to turn ON/OFF
Memory	Last 2,000 Records
Strip Incubation Time	1 Minute
Wavelength	525 and 635 nm
Standard Strips	8, 9, 10, 11 Parameters (5 mm x 108 mm)
Additional Strips Available	1-11 Parameters (5 mm x 108 mm); see URS Parameters
Total Combinations Per Analyzer	4 Combinations
Waste Disposal Capacity	Up to 150 Strips
Analyzer Ports	Standard RS232C Port for Barcode Reader or Data Transfer 25 Pin Parallel Port for External Printer
Capabilities	Internal Thermal Printer (included) RS232C Barcode Reader (optional) Optional External Printer (not included) RS232C Data Transfer Cable (optional)
Major Readable Barcodes	Code 128, Code 39, Codabar (NW-7), Interleaved 25, UPC-A, UPC-E, EAN 8, EAN 13
Calibration	Automatic
Available Languages on the Screen	English and additional language(s)
Operating Conditions	0-40°C (32-104°F); ≤85% RH
Storage Conditions	-5-50°C (23-122°F); ≤90% RH
Power Source	100-240 VAC, 50-60 Hz
Dimensions (L x W x H)	36.6 cm x 28.3 cm x 19.5 cm (14.4" x 11.1" x 7.7")
Display Dimensions (L x W)	11.5 cm x 9.0 cm (4.5" x 3.5")
Weight	4.0 kg (8.8 lbs)

Ordering Information

Product Name	Catalog No.	Components	Kit Box Dimensions (L x W x H) & Weight	Carton Dimensions (L x W x H) & Weight	Number of Kits/Carton
U500 Urine Analyzer	U211-101✓	1 Urine Analyzer 1 Strip Platform/Waste Tray 2 Printer Paper Rolls	2 Fuses (2.0A) 1 Power Cord 1 Instruction Manual	51.0 cm x 42.0 cm x 38.5 cm; 7 kg 20.1" x 16.5" x 15.2"; 246.9 oz	1
U500 Urine Analyzer with Barcode Reader	U211-111✓	1 Urine Analyzer 1 Strip Platform/Waste Tray 2 Printer Paper Rolls 1 Barcode Reader (RS232C)	2 Fuses (2.0A) 1 Power Cord 1 Serial Splitter Cable (RS232C) 1 Instruction Manual	55.0 cm x 55.0 cm x 55.0 cm; 9.2 kg 21.7" x 21.7" x 21.7"; 324.5 oz	1
Barcode Reader	U221-111✓†	1 Barcode Reader (RS232C)	1 Serial Splitter Cable (RS232C)	23.6 cm x 10.8 cm x 7.8 cm; 0.482 kg 9.3" x 4.3" x 3.1"; 17.0 oz	22
Printer Paper Rolls	U121-101	4 Printer Paper Rolls	Thermal Paper (0.06 m x 20 m): 200 results/roll Sticker Paper (0.06 m x 9 m): 100 results/roll	12.0 cm x 12.0 cm x 6.5 cm; 0.360 kg 4.7" x 4.7" x 2.6"; 12.7 oz	50
U500 Data Transfer Kit	U221-131✓	1 Data Transfer Cable (RS232C)	1 Package Insert	12.0 cm x 12.0 cm x 6.5 cm; 0.40 kg 4.7" x 4.7" x 2.6"; 14.1 oz	8

We also offer other rapid diagnostic and medical products:

Blood Glucose Monitoring Systems, Immunoassay EIA/ELISA and more.

✓ CE Marked for sale in the European Community

† Cleared for US 510(k)



Mission[®]

Urine Controls

Simply validate
visual and analyzer
urinalysis with
Mission[®] Liquid and
Dry Strip Urine
Controls!

- *Reliable*
- *Quick and Easy*
- *Available in Liquid and Dry Strip*



Global Diagnostics for Local Markets™

Mission® Urine Controls

Reliable

- Use with Mission® and Mission® Expert Urinalysis Reagent Strips and Urine Analyzers for optimum quality control
- Validate urinalysis results and prevent procedure errors
- Control Level 1 provides negative results for LEU, NIT, URO, PRO, pH, BLO, SG, KET, BIL, GLU, ASC, ALB^{test} and CRE^{test}
- Control Level 2 provides positive results for LEU, NIT, URO, PRO, pH, BLO, SG, KET, BIL, GLU, ALB^{test} and CRE^{test} with negative results for ASC

Quick and Convenient Testing

- Ensures accurate results for all parameters
- Obtain quick results in any setting
- Competitively priced

Two Types of Urine Controls Available

Liquid Urine Control

- Ready-to-use without dissolving in distilled water
- 24 months shelf life for unopened controls at 2-8°C
- Two Packaging Options
 - Dropper Tip Bottles-Current packaging now available in separate positive and negative levels!
 - Dropper tip bottles provide efficient use of the control solution
 - Easily drop the control solution onto each reagent pad using the dropper tip bottle
 - Control can be used up to 40 times within 30 days at room temperature
 - Diptube-New packaging available in separate positive and negative levels!
 - Diptube packaging allows for quick testing similar to using a urine specimen
 - Simply dip the strip into the control solution and read results
 - Control can be used up to 20 times within 30 days at room temperature

Dry Strip Urine Control

- Portable for use anywhere with no refrigeration required
- Dissolve the dry strip urine control in distilled water, dip urine strip in the control solution, then compare to color chart
- Each control solution can be used for up to 12 tests at 2-30°C within 8 hours for all parameters
- 24 months shelf life at 2-30°C for unopened controls



Specifications

Features		Specifications		
Product Name		Liquid Urine Control	Liquid Diptube Urine Control	Dry Strip Urine Control
Test Parameters		LEU, NIT, URO, PRO, pH, BLO, SG, KET, BIL, GLU, ASC, ALB, CRE (13)		
Solution Detection Levels	Level 1	Negative: LEU, NIT, URO, PRO, pH, BLO, SG, KET, BIL, GLU, ASC, ALB, CRE		
	Level 2	Positive: LEU, NIT, URO, PRO, pH, BLO, SG, KET, BIL, GLU, ALB and CRE, Negative ASC		
Compatible Urine Strips		Mission® Urinalysis Reagent Strips, Mission® Expert Urinalysis Reagent Strips		
Reading Time/Stability		Refer to insert	Refer to insert	Refer to insert
Storage Temperature		2-8°C	2-8°C	2-30°C
Unopened Control Shelf Life		24 months	24 months	24 months
Opened Control Stability		30 days at 15-30°C or until the expiration date at 2-8°C	30 days at 15-30°C or until the expiration date at 2-8°C	2-30°C: 3 months for Dry Strip; 8 hours for Control Solution for all parameters
Maximum Tests per Unit		20 or 40 tests/bottle	20 tests/diptube	12 tests/control solution of 1 dry strip

Ordering Information

Product Name	Catalog No.	Components	Kit Box Dimensions (LxWxH) & Weight	Carton Dimensions (LxWxH) & Weight	# Kits/Carton
Liquid Urine Control [†]	U021-011: Combo	Level 1: 3 x 10 mL/bottle; Level 2: 3 x 10 mL/bottle	85 mm x 55 mm x 60 mm; 107 g	400 mm x 270 mm x 345 mm; 5.2 kg	198
		Level 1: 3 x 5 mL/bottle; Level 2: 3 x 5 mL/bottle	85 mm x 55 mm x 60 mm; 75 g	400 mm x 270 mm x 345 mm; 4.2 kg	198
		Level 1: 1 x 10 mL/bottle; Level 2: 1 x 10 mL/bottle	55 mm x 28 mm x 60 mm; 41 g	400 mm x 270 mm x 345 mm; 6.6 kg	228
		Level 1: 1 x 5 mL/bottle; Level 2: 1 x 5 mL/bottle	55 mm x 28 mm x 60 mm; 31 g	400 mm x 270 mm x 345 mm; 5.5 kg	228
	U021-021: Level 1; U021-031: Level 2	6 x 10 mL/bottle	85 mm x 55 mm x 60 mm; 107 g	400 mm x 270 mm x 345 mm; 5.2 kg	198
		6 x 5 mL/bottle	85 mm x 55 mm x 60 mm; 75 g	400 mm x 270 mm x 345 mm; 4.2 kg	198
		2 x 10 mL/bottle	55 mm x 28 mm x 60 mm; 41 g	400 mm x 270 mm x 345 mm; 6.6 kg	228
		2 x 5 mL/bottle	55 mm x 28 mm x 60 mm; 31 g	400 mm x 270 mm x 345 mm; 5.5 kg	228
Liquid Diptube Urine Control [†]	U021-071: Combo	Level 1: 2 x 12 mL/diptube; Level 2: 2 x 12 mL/diptube	130 mm x 55 mm x 55 mm; 101 g	385 mm x 255 mm x 320 mm; 4.7 kg	30
		Level 1: 1 x 12 mL/diptube; Level 2: 1 x 12 mL/diptube	130 mm x 55 mm x 55 mm; 62 g	385 mm x 255 mm x 320 mm; 3.5 kg	30
	U021-081: Level 1; U021-091: Level 2	4 x 12 mL/diptube	130 mm x 55 mm x 55 mm; 101 g	385 mm x 255 mm x 320 mm; 4.7 kg	30
		2 x 12 mL/diptube	130 mm x 55 mm x 55 mm; 62 g	385 mm x 255 mm x 320 mm; 3.5 kg	30
Dry Strip Urine Control [†]	U021-041: Combo	Level 1: 1 x 25 strips/canister; Level 2: 1 x 25 strips/canister	100 mm x 51 mm x 110 mm; 126 g	280 mm x 280 mm x 260 mm; 3.6 kg	24
		Level 1: 1 x 10 strips/canister; Level 2: 1 x 10 strips/canister	100 mm x 51 mm x 110 mm; 106 g	280 mm x 280 mm x 260 mm; 3.1 kg	24
	U021-051: Level 1; U021-061: Level 2	2 x 25 strips/canister	100 mm x 51 mm x 110 mm; 126 g	280 mm x 280 mm x 260 mm; 3.6 kg	24
		2 x 10 strips/canister	100 mm x 51 mm x 110 mm; 106 g	280 mm x 280 mm x 260 mm; 3.1 kg	24

✓ CE Marked for sale in the European Community CE
 † FDA 510(k) Cleared

We also offer other rapid diagnostic and medical products for:

Blood Glucose Monitoring Systems, Clinical Chemistry including Urinalysis, Immunoassay EIA/ELISA and more.

Contact us for worldwide distribution and custom manufacturing (OEM) opportunities



Date: 05/Jan/2023

STATEMENT

We, Atlas Medical having a registered office at Ludwig-Erhard-Ring 3, 15827 Blankenfelde-Mahlow, Berlin, Germany assign SRL Sanmedico having a registered office at A. Corobceanu Street 7A, apt.9, Chisinau MD-2012, Moldova, as authorized representative in correspondence with the conditions of directive 98/79/EEC.

We declare that the company mentioned above is authorized to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova.

On Behalf of Manufacturer:

General Manager

Haya Amawi

Signature: _____

Date: _____

Atlas Medical GmbH
Ludwig - Erhard Ring 3
15827 Blankenfelde - Mahlow
Tel. (0049) 33708 - 355030

Atlas Medical: Ludwig-Erhard-Ring 3, 15827 Blankenfelde-Mahlow, Berlin, Germany,
Tel: +4933708355030

Regulatory Office: William James House, Cowley Rd, Cambridge, CB4 0WX, United Kingdom
Tel: +44 (0) 1223 858 910

Middle East Site: P.O Box 204, King Abdullah II Industrial Estate, Amman, 11512, Jordan
Tel: +962 6 4026468


CE Declaration of Conformity

We,
Atlas Medical GmbH
 Head office: Ludwig-Erhard-Ring 3
 15827 Blankenfelde-Mahlow Germany
 Tel: +49(0)33708355030
 Email: info@atlas-medical.com

Middle East Site: Sahab Industrial Zone Area, King Abdullah II Industrial City
 Amman 11512, Jordan
 Tel.: +962 6 4026468
 Fax: +962 6 4022588
 Email: info@atlas-medical.com

Declare our responsibility that the following product:

Product Code	Product Name	Class	GMDN code
8.00.18.0.0005	RPR Carbon Antigen Reagent, 5 ml/vial	General-IVD	32450
8.00.18.2.1000	RPR Carbon Antigen 1000ml/bottle	General-IVD	32450
8.00.18.0.0050	RPR Carbon Antigen Kit, 50 Tests	General-IVD	32450
8.00.18.1.0050	RPR Carbon Antigen Kit, 50 Tests, White Glass Slide.	General-IVD	32450
8.00.18.2.0500	RPR Carbon Antigen Kit, 500 Tests (2ml latex, 2x0.5 ml control) Without card.	General-IVD	32450
8.00.18.3.0500	RPR Carbon Antigen Kit, 500 Tests (10ml latex, 2x0.5 ml control) Without card, stirring sticks.	General-IVD	32450
8.00.18.0.0100	RPR Carbon Antigen Kit, 100 Tests (2ml latex, 2x0.5 ml control)	General-IVD	32450
8.00.18.2.0100	RPR Carbon Antigen Kit, 100 Tests (2ml latex, 2x0.5 ml control +White Glass slide stirring sticks)	General-IVD	32450
8.00.18.0.0025	RPR Carbon Antigen Kit, 25 Tests (0.5ml latex, 2x0.5 ml control)	General-IVD	32450
8.00.18.0.0150	RPR Carbon Antigen Kit, 150 Tests	General-IVD	32450
8.00.18.0.0200	RPR Carbon Antigen Kit, 200 Tests	General-IVD	32450
8.00.18.0.0250	RPR Carbon Antigen Kit, 250 Tests	General-IVD	32450

Atlas Medical	First issue date	Date of review	Management approval	MRXDO10F.10 08.02.2011
	September.2021	06.09.2021		

Amin Al-Habashat
 RA Manager

Declaration Ref No: DC21-0193

8.00.18.0.0500	RPR Carbon Antigen Kit,500 Tests	General-IVD	32450
8.00.18.0.1000	RPR Carbon Antigen Kit, 1000 Tests	General-IVD	32450
8.00.18.4.0500	RPR Carbon Antigen Kit,500 Tests (3x3.4ml reagent,2x1 controls)	General-IVD	32450
8.00.18.5.0500	RPR Carbon Antigen Kit, 500 Tests, (3x3.4ml reagent,2x1 controls)	General-IVD	32450
8.00.18.8.0500	RPR Carbon Antigen 500 Test (10ml reagent) without Control's.	General-IVD	32450
8.00.18.9.0050	RPR Carbon Antigen Kit, (5x10ml Reagent,2x2ml Control) , white glass Slide, Stirring Stick.	General-IVD	32450
8.33.04.0.0001	RPR Positive control	General-IVD	32450
8.33.04.1.0001	RPR Positive control ,Bulk	General-IVD	32450
8.33.04.0.0100	RPR Positive control(100ml/vial)	General-IVD	32450
8.33.04.0.0500	RPR Positive control(500ml/bottle)	General-IVD	32450
8.33.08.0.0001	RPR Negative control	General-IVD	32450

Is produced under Atlas quality system (ISO13485: 2016) supported by GMED certificate:

Certificate N^o.: 36655 rev 1

Expiry Date: October 8th.2023

and complies with the essential requirements of
In Vitro Diagnostic Medical Devices Directive 98/79/EC Annex I
And

EN ISO 18113-1, -2 :2011, EN ISO 15223:2016

**EN ISO 14971:2019, EN ISO 23640 :2015 , ISO 2859 :2017,
EN 13612:2002, EN 13641:2002 , EN 13975:2003, ISO 13485:2016**

And

Intended for In-Vitro Professional use only.

This Declaration includes the batches produced beyond this day according to the product Lot Log.


Manufacturer

Atlas Medical GmbH

Ludwig-Erhard-Ring 3

15827 Blankenefelde-Mahlow Germany.



Atlas Medical	First issue date	Date of review	Management approval	MRXDO10F.10 08.02.2011
	September.2021	06.09.2021		

Amir Al-Hadad
RA Manager

CE Declaration of Conformity

We,
Atlas Medical GmbH
Head office: Ludwig-Erhard-Ring 3
15827 Blankenfelde-Mahlow Germany
Tel: +49(0)33708355030
Email: info@atlas-site.com

Middle East Site: : Sahab Industrial Zone Area, King Abdullah II Industrial City
Amman 11512, Jordan
Tel.: +962 6 4026468
Fax: +962 6 4022588
Email: info@atlas-medical.com

Declare our responsibility that the following product:

Blood Grouping Reagents:
(Anti-A Monoclonal Reagent, Anti-B Monoclonal Reagent , Anti-AB Monoclonal Reagent and
Anti-D IgG/IgG blend Reagent)
see the attached list of variants

That are classified as Annex II, list A

Is produced under Atlas quality system (ISO13485: 2016) supported by GMED certificate and
complies with the essential requirements of

In Vitro Diagnostic Medical Devices Directive 98/79/EC

And

EN ISO 18113-1, -2 :2011, EN ISO 15223:2016
EN ISO 14971:2019, EN ISO 23640 :2015 , ISO 2859 :2017,
EN 13612:2002, EN 13641:2002 , EN 13975:2003,
EN ISO 13485:2016, EN 62366-1:2020

And

Intended for In-Vitro Professional use only.

Conformity Assessment Route:

Annex IV.3 –Approval full Quality Assurance System.

Annex IV.4-EC Design Examination (of the product)


Notified Body:


G-MED	CE	0459
-------	----	------

GMED, Laboratoire national de métrologie et d'essais
1 rue Gaston Boissier 75015 Paris
Tél. : 01 40 43 37 00 , TVA:FR 28 839 022 522


EC Certificates No.:

- CE Certificate of Approval full Quality Assurance System: 33540 rev4.
- CE Certificate Of EC Design Examination: 33544 rev3.


Atlas Medical GmbH	Start of CE Marking	Date of expiry	Name & Position	Signature	MRXDO10F.11 21.10.2013
	09 th october 2017	26 th May 2025	Amani Al-hababbeh (RA Manager)		




Product Code	Product Name	GMDN Code
8.02.00.0.0010	Anti-A Monoclonal Reagent (Titer: 1/512), 10ml/vial, 1 vial/Carton Box	52532
8.02.00.1.0100	Anti-A Monoclonal Reagent (Titer: 1/512), 10ml/vial. 10 vials / Plastic Pack	52532
8.02.00.1.0180	Anti-A Monoclonal Reagent (Titer: 1/512), 10ml/vial. 18 vials / Carton Box	52532
8.02.01.0.0010	Anti-B Monoclonal Reagent (Titer: 1/512), 10ml/vial, / Carton Box	52538
8.02.01.1.0100	Anti-B Monoclonal Reagent (Titer: 1/512), 10ml/vial, 10 vials / Plastic Pack	52538
8.02.01.1.0180	Anti-B Monoclonal Reagent (Titer: 1/512), 10ml/vial, 18 vials / Carton Box	52538
8.02.02.0.0010	Anti-AB Monoclonal Reagent (Titer: 1/512), 10ml/vial, 1 vial/ Carton Box	46442
8.02.02.1.0100	Anti-AB Monoclonal Reagent (Titer: 1/512), 10ml/vial, 10 vials/Plastic Pack	46442
8.02.02.1.0180	Anti-AB Monoclonal Reagent (Titer: 1/512), 10ml/vial, 18 vials/Carton Box	46442
8.02.03.0.0010	Anti-D IgG/IgM Blend Reagent (Titer: 1/128), 10ml/vial, 1 vial/ Carton Box	52647
8.02.03.1.0100	Anti-D IgG/IgM Blend Reagent (Titer: 1/128), 10ml/vial, 10 vials / Plastic Pack	52647
8.02.03.1.0180	Anti-D IgG/IgM Blend Reagent (Titer: 1/128), 10ml/vial, 18 vials / Carton Box	52647
8.02.04.0.0010	Anti-A Monoclonal Reagent (Titer: 1/256), 10ml/vial, 1 Vial/Carton Box	52532
8.02.04.0.0100	Anti-A Monoclonal Reagent (Titer: 1/256), 10ml/vial, 10 vials / Plastic Pack	52532
8.02.05.0.0010	Anti-B Monoclonal Reagent (Titer: 1/256), 10ml/vial, 1vial/Carton Box	52538
8.02.05.0.0100	Anti-B Monoclonal Reagent (Titer: 1/256), 10ml/vial, 10 vials /Plastic Pack	52538
8.02.05.6.0030	ABO Set (Anti-A (1/256), Anti-B (1/256), Anti-D (1/64)),3x10ml / plastic Pack	45308
8.02.05.7.0020	ABO Set: Anti-A (1/256), Anti-B (1/256), 2x10ml /Plastic Pack	52695
8.02.06.0.0010	Anti-AB Monoclonal Reagent (Titer: 1/256), 10ml/vial, 1vial/Carton Box	46442
8.02.06.1.0100	Anti-AB Monoclonal Reagent (Titer: 1/256), 10ml/vial,10 vials /Plastic Pack	46442
8.02.06.1.0180	Anti-AB Monoclonal Reagent (Titer: 1/256), 10ml/vial,18 vials / Carton Box	45308
8.02.07.0.0010	Anti-D IgG/IgM Blend Reagent (Titer: 1/64), 10ml/vial, 1Vial/ Carton Box	52647
8.02.07.1.0100	Anti-D IgG/IgM Blend Reagent (Titer: 1/64), 10ml/vial, 10 vials / Plastic Pack	52647

Atlas Medical GmbH	Start of CE Marking	Date of expiry	Name & Position	Signature	MRXDO10F.11 21.10.2013
	09 th october 2017	26 th May 2025	Amani Al-hababbeh (RA Manager)		

8.02.47.0.0030	ABO Set (Anti-A (1/512), Anti-B (1/512), Anti-D (1/128)), 3x10ml/Plastic Pack	45308
8.02.47.1.0030	ABO Set (Anti-A (1/256), Anti-B (1/256), Anti-D (1/64)), 3x10ml /Carton Box.	45308
8.02.47.3.0030	ABO Set (Anti-A (1/256), Anti-B (1/256), Anti-D (1/64)), 3x10ml /Plastic Pack	45308
8.02.47.5.0030	ABO Set (Anti-A (1/256), Anti-B (1/256), Anti-D (1/128)), 3x10ml/Plastic Pack	45308
8.02.49.0.0040	ABO Set (Anti-A (1/256), Anti-B (1/256), Anti-AB (1/256), Anti-D (1/64)), 4x10ml/Carton Box	45308
8.02.49.2.0040	ABO Set (Anti-A (1/256), Anti-B (1/256), Anti-AB (1/256), Anti-D (1/128)), 4 x 10ml, 4 vials/Plastic Pack	45308
8.02.53.0.0040	ABO Set (Anti-A (1/512), Anti-B (1/512), Anti-AB (1/512) Anti-D (1/128)), 4x10ml/Plastic Pack	45308
8.02.53.1.0040	ABO Set (Anti-A (1/512), Anti-B (1/512), Anti-AB (1/512) Anti-D (1/128)), 4x10ml, 4vials/Plastic Pack	45308
8.02.70.0.0010	Anti-A monoclonal reagent , Titer (1/1024), 10 ml/vial, 1Vial/ Carton Box	52532
8.02.71.0.0010	Anti-B Monoclonal reagent (Titer: 1/1024) , 10 ml/vial ,1Vial/ Carton Box	52538
8.02.72.0.0010	Anti-AB Monoclonal reagent (Titer: 1/1024) , 10 ml/vial , 1Vial/ Carton Box	45308
8.02.85.0.0010	Anti-D IgG/IgM Blend Reagent , Titer 1/256, 10ml/vial, 1Vial/ Carton Box	52647



Atlas Medical GmbH	Start of CE Marking	Date of expiry	Name & Position	Signature	MRXDO10F.11
	09 th october 2017	26 th May 2025	Amani Al-hababbeh (RA Manager)		21.10.2013

Declaration Ref No: DC21-0035

CE Declaration of Conformity

According to Annex III of the IVD Directive 98/79/EC

We,

Atlas Medical

Head office: Ludwig-Erhard-Ring 3
Blankenfelde-Mahlow, Germany.
Tel: +49 - 33708 – 3550 30
Email: info@atlas-medical.com

Middle East Site: Sahab Free Zone Area, P. O. Box 212555, Amman, Jordan.
Tel.: +962 6 4026468
Fax: +962 6 4022588
Email: info@atlas-medical.com

Declare our responsibility that the following product:


See Attached list


- Comply with all essential requirements (Annex I) of the IVD Directive 98/79/EC. This compliance has been properly documented and covers the items listed in Annex I of the IVD Directive.
- This product is produced under Atlas quality system (ISO13485:2016) issued by GMED:
Certificate N°: 36655 rev 1
Expiry Date: October 8th.2023
- Comply with the essential requirements of following standards (EN 18113-1, -2, -4:2011, EN ISO 15223:2016, EN ISO 23640:2015, EN ISO 14971:2019, ISO 2859/1:1999, EN ISO 13612:2002, EN ISO 13641:2002).

And

Intended for In-Vitro Professional use only.

Manufacturer
Atlas Medical
Ludwig-Erhard-Ring 3
Blankenfelde-Mahlow , Germany.



Atlas Medical	Issue date	Date of review	Management approval	MRXDO10F.10 08.02.2011
	March.2021	09.03.2021		

CE Declaration of Conformity

According to Annex III of the IVD Directive 98/79/EC

Product Description
8.00.02.0.0100 : ASO Latex Kit, 100 Tests (4ml Latex, 2x1.0ml controls).
8.00.00.0.0100: CRP Latex Kit, 100 Tests (4 ml Latex, 2x1.0 ml Controls)
8.00.04.0.0100: RF Latex Kit, 100 Tests (4ml Latex, 2x1.0ml controls)
8.00.17.0.0100: D-Dimer Latex Kit, 100 Tests
8.00.13.0.0300 : Streptococcus Latex Kit, 6 Groups, 6x50 Tests (5x1.5ml Latex (A,B,C,G,F), 1x3ml Latex(D), 1x1.0ml Positive Control, 1x2ml Extraction Reagent E, 1x1.5ml Extraction Reagent 1, 1x1.5ml Extraction Reagent 2, 2x2.5ml Extraction Reagent 3, Stirring Sticks, Glass Slide).
8.00.18.3.0500 : RPR Syphilis (Coarse Grain) Kit, 500 Tests (10 ml latex, 2x1ml control) Without card, stirring sticks.
8.00.18.3.1000 RPR Carbon Antigen (Coarse Grain) Kit, 1000 Tests (Reagent only).



GMED certifie que le système de management de la qualité développé par
GMED certifies that the quality management system developed by

ATLAS MEDICAL GmbH
Ludwig-Erhard-Ring 3
15827 Blankenfelde-Mahlow GERMANY

pour les activités
for the activities

Conception et développement, fabrication et vente de dispositifs médicaux de diagnostic in vitro .

Design and Development, Manufacturing and Sales of in vitro diagnostic medical devices.

réalisées sur le(s) site(s) de
performed on the location(s) of

Voir addendum

See addendum

est conforme aux exigences des normes internationales
complies with the requirements of the international standards

ISO 13485: 2016

Début de validité / Effective date October 9th, 2020 (included)

Valable jusqu'au / Expiry date : October 8th, 2023 (included)

Etabli le / Issued on : October 8th, 2020




**CERTIFICATION
DE SYSTEMES
DE MANAGEMENT**
Accréditation n°4-0608
Liste des sites accrédités
et portée disponible sur
www.cofrac.fr

GMED N° 36655-1

Ce certificat est délivré selon les règles de certification GMED / This certificate is issued according to the rules of GMED certification

Renouvelle le certificat 36655-0



On behalf of the President
Béatrice LYS
Technical Director

GMED • Société par Actions Simplifiée au capital de 300 000 € • Organisme Notifié/Notified Body n° 0459
Siège social : 1, rue Gaston Boissier - 75015 Paris • Tél. : 01 40 43 37 00 • gmed.fr

Ce certificat couvre les activités et les sites suivants :
This certificate covers the following activities and sites:

French version :

Conception et développement, fabrication et vente de dispositifs médicaux de diagnostic *in vitro* à usage professionnel et/ ou d'autodiagnostic, dans les domaines du groupage sanguin, de la microbiologie, de la biochimie, de la toxicologie, de l'oncologie, de la cardiologie, de l'histologie, de l'endocrinologie et des maladies infectieuses, dans les techniques d'Agglutination/ ELISA/ Tests rapides/ Colorimétrie/ Disques antibiotiques.

English version:

Design and Development, Manufacturing and Sales of in vitro diagnostic medical devices for professional use and/or for self-testing, in the field of Immunohematology, Microbiology, Biochemistry, Toxicology, Oncology, Cardiology, Histology, Endocrinology Biosensors and Infectious diseases, in techniques of Agglutination/ ELISA/ Rapid tests/ Colorimetry/Antibiotic disks.

**ATLAS MEDICAL GmbH
Ludwig-Erhard-Ring 3
15827 Blankenfelde-Mahlow
GERMANY**

French version:

Siège social, responsable de la mise sur le marché

English version:

Headquarter, legal manufacturer

**Sahab Industrial Zone Area
King Abdullah II Industrial City
Amman 11512
JORDAN**

French version:

Conception, fabrication et contrôle final

English version:

Design, manufacture and final control

**William James House
Cowley Road,
Cambridge, CB OWX
United Kingdom**

French version:


Contact réglementaire

English version:

Regulatory Administration

3 sites / 3 sites

DocuSigned by:

Beatrice Lys
EF33BDA9BAA04A3...


**On behalf of the President
Béatrice LYS
Technical Director**

ATLAS C-REACTIVE PROTEIN (CRP) LATEX KIT

For the qualitative and semi-quantitative measurement of C-reactive protein (CRP) in human serum.

IVD For in -vitro diagnostic and professional use only

2°C  8°C
Store at 2-8°C

INTENDED USE

Atlas C-Reactive Protein (CRP) is used to measure the CRP in human serum qualitatively and semi- quantitatively.

INTRODUCTION

C-reactive protein (CRP), the classic acute-phase of human serum, is synthesized by hepatocytes. Normally, it is present only in trace amounts in serum, but it can increase as much as 1,000-fold in response to injury or infection. The clinical measurement of CRP in serum therefore appears to be a valuable screening test for organic disease and a sensitive index of disease activity in inflammatory, infective and ischemic conditions. MacLeod and Avery found that antibody produced against purified CRP provided a more sensitive test than the C-polysaccharide assay. Since that time a number of immunological assays have been devised to measure CRP such as capillary precipitation, double immunodiffusion and radical immunodiffusion.

The CRP reagent kit is based on the principle of the latex agglutination assay described by Singer and Plotz. The major advantage of this method is the rapid two (2) minute reaction time.

PRINCIPLE

The CRP reagent kit is based on an immunological reaction between CRP Antisera bound to biologically inert latex particles and CRP in the test specimen. When serum containing greater than 6 mg/L CRP is mixed with the latex reagent, visible agglutination occurs.

MATERIALS

MATERIALS PROVIDED

- CRP Latex Reagent: Latex particles coated with goat IgG anti-human CRP, pH 8.2 **MIX WELL BEFORE USE.**

- CRP Positive Control Serum: A stabilized pre-diluted human serum containing >20mg/L CRP.
- CRP Negative Control Serum: A stabilized pre-diluted animal serum.
- Glass Slides.
- Stirring Sticks.

MATERIALS REQUIRED BUT NOT PROVIDED

- Mechanical rotator with adjustable speed at 80-100 r.p.m.
- Vortex mixer.
- Pipettes 50 µL.
- Glycine Buffer (20x): add one part to nineteen parts of distilled water before use.

PRECAUTIONS

- Reagents containing sodium azide may be combined with copper and lead plumbing to form highly explosive metal azides. Dispose of reagents by flushing with large amounts of water to prevent azide buildup.
- For In Vitro diagnostic use.
- Positive and negative controls prepared using human serum found negative for hepatitis B surface antigen (HBsAg) by FDA required test; however, handle controls as if potentially infectious.
- Accuracy of the test depends on the drop size of the latex reagent (40µl). Use only the dropper provided with the latex and hold perpendicularly when dispensing.
- Glass slides should be thoroughly rinsed with water and wiped with lint-free tissue after each use.

STORAGE AND STABILITY

- Reagents are stable until specified expiry date on bottle label when stored refrigerated (2 - 8°C). **DO NOT FREEZE.**
- The CRP latex reagent, once shaken must be uniform without visible clumping. When stored refrigerated, a slight sedimentation may occur and should be considered normal.
- Do not use the latex reagent or controls if they become contaminated.

SPECIMEN COLLECTION AND STORAGE

- Use fresh serum collected by centrifuging clotted blood.

- If the test cannot be carried out on the same day, store the specimen for 7 days at 2-8 °C and for 3 months at -20°C.
- For longer periods the sample must be frozen.
- As in all serological tests, hemolytic or contaminated serum must not be used.
- Do not use plasma.

PROCEDURE

A.QUALITATIVE TEST:

- Allow the reagents and samples to reach room temperature. The sensitivity of the test may be reduced at low temperatures.
- Place 40 µL of the sample and one drop of each Positive and Negative controls into separate circles on the slide test.
- Mix the CRP-latex reagent vigorously or on a vortex mixer before using and add one drop (40 µL) next to the samples to be tested.
- Mix the drops with a stirrer, spreading them over the entire surface of the circle. Use different stirrers for each sample.
- Place the slide on a mechanical rotator at 80-100 r.p.m. for 2 minutes. False positive results could appear if the test is read later than two minutes.

B.SEMI-QUANTITATIVE TEST:

- Make serial two fold dilutions of the sample in 9 g/L saline solution.
- Proceed for each dilution as in the qualitative method.

QUALITY CONTROL

Positive and Negative controls are recommended to monitor the performance of the procedure, as well as a comparative pattern for a better result interpretation.


All result different from the negative control result, will be considered as a positive.

INTERPRETATION OF RESULTS

A.QUALITATIVE TEST:

A **negative** reaction is indicated by a uniform milky suspension with no agglutination as observed with the CRP Negative Control.

A **positive** reaction is indicated by any observable agglutination in the reaction mixture. The specimen reaction should be compared to the CRP Negative Control (Fig. 1).



Positive Negative

Figure 1

B. Semi-QUANTITATIVE TEST:

The approximate CRP concentration in the patient sample is calculated as follow:

6×CRP titer = ---- mg/L

INTERFERENCES

NONE INTERFERING SUBSTANCES:

- Hemoglobin (10g/dl)
- Bilirubin(20mg/dl)
- Lipemia(10g/dl)
- Other substances interfere, such as RF (100IU/ml).

NOTE

- High CRP concentration samples may give negative results .Retest the sample again using a drop of 20µl.
- The strength of agglutination is not indicative of the CRP concentration in the samples tested.
- Clinical diagnosis should not be made on findings of a single test result, but should integrate both clinical and laboratory data.

LIMITATIONS

1. Reaction time is critical. If reaction time exceeds two (2) minutes, drying of the reaction mixture may cause false positive results.
2. Freezing the CRP Latex Reagent will result in spontaneous agglutination.
3. Intensity of agglutination is not necessarily indicative of relative CRP concentration; therefore, screening reactions should not be graded.
4. A false negative can be attributed to a prozone phenomenon (antigen excess). It is recommended, therefore, to check all negative sera by retesting at a 1:10 dilution with glycine buffer.

REFERENCE VALUES

Up to 6 mg/L. Each laboratory should establish its own reference range.

PERFORMANCE CHARACTERISTICS

- **Sensitivity:** 6(5-10) mg/L
- **Prozone effect:** No prozone effect was detected up to 1600 mg/L
- **Diagnostic sensitivity:** 95.6 %.
- **Diagnostic specificity:** 96.2 %.

REFERENCES

1. Pepys, M.B.. Lancet 1:653 (1981).
2. Werner, M.. Clin.Chem. Acta 25:299 (1969).
3. MacLeod, C.M., et. al.. J. Exp. Med 73:191 (1941).
4. Wood, HF., et. al.. J. Clin. Invest. 30: 616 (1951).
5. Mancini, G., et. al. Immunochemistry 2:235 (1965).
6. Singer, J.M., et. al.. Am. J. Med 21: 888 (1956).
7. Fischer, C.L., Gill,. C.W.. In Serum Protein Abnormalities. Boston, Little, Brown and Co., (1975).



ATLAS MEDICAL














William James House,
Cowley Road, Cambridge,
CB4 0WX, UK

Tel: +44 (0) 1223 858 910

Fax: +44 (0) 1223 858 524

PPI005A01

Rev H (06.06.2017)

	Catalogue Number		Store at
	For In-Vitro Diagnostic use		Caution
	Number of tests in the pack		Read product insert before use
	Lot (batch) number		Manufacturer
	Fragile, handle with care		Expiry date
	Manufacturer fax number		Do not use if package is damaged
	Manufacturer telephone number		

Blood Grouping Reagents:

Anti-A Monoclonal Reagent, Anti-B Monoclonal Reagent, Anti-AB Monoclonal Reagent, Anti-D IgG/IgM blend Reagent, & Their variants

SLIDE AND TUBE TESTS

IVD For In-Vitro and professional use only

2°C  8°C
Store at 2- 8°C

INTENDED USE

The blood grouping reagents are used to detect the presence or absence of A, B or Rhesus Antigens on the surface of human red blood cells based on hemagglutination using slide or tube test techniques in whole blood samples or anticoagulant blood samples collected in EDTA, citrate or heparin tubes.

INTRODUCTION & PRINCIPLES

Blood grouping reagents are prepared from In-Vitro culture supernatants of hybridized immunoglobulin-secreting mouse cell lines. The reagents are diluted with phosphate buffer containing sodium chloride, EDTA and bovine albumin to give reagents that are optimized for use in tube and slide procedures. **Anti-A monoclonal reagent is colored with acid blue (patent blue) dye, Anti-B monoclonal reagent is colored with acid yellow (tartrazine) dye, and Anti-AB monoclonal reagent is not colored.** The test procedure is based on hemagglutination principle, where red cells possessing the antigen agglutinate in the presence of the corresponding antibody indicating that the result is positive. The test is considered negative when no agglutination appears.

Anti-D IgG/IgM blend reagent is prepared from carefully blended human monoclonal IgM and IgG. Anti-D IgG/IgM blend reagent is suitable for slide and tube test procedures. The reagent will directly agglutinate Rh D positive cells, including majority of variants (but not D^{vi}) and a high proportion of weak D (Du) phenotypes. The reagent will agglutinate category D^{vi} and low grade weak D (D^u) phenotypes by the indirect anti-globulin techniques.

Anti-D IgG/IgM blend reagent is diluted with a sodium chloride solution, sodium phosphate solution and bovine albumin (sodium caprylate free). Anti-D IgG/IgM blend reagent is not colored. The procedure is based on hemagglutination principle, where red cells' possessing the antigen agglutinates in the presence of the corresponding antibody in the reagent indicating that the result is positive. The test is considered negative when no agglutination appears.

MATERIALS

MATERIALS PROVIDED

Blood Grouping Reagents:

- Anti-A monoclonal reagent (10 ml/vial), Clone: (9113D10).
- Anti-B monoclonal reagent (10 ml/vial), Clone: (9621A8).
- Anti-AB monoclonal reagent (10ml/vial), Clone: (152D12+9113D10).
- Anti-D IgG/IgM Blend reagent (10 ml/vial), Clone: (P3X61 + P3X21223B10 + P3X290 + P3X35).

MATERIALS NEEDED BUT NOT PROVIDED

- Plastic test tube or glass.
- Isotonic saline solution (% 0.9) NaCl).
- Applicator sticks.
- Centrifuge (100-1200 (g) for tube test).
- Timer.
- Incubator
- Anti-Human Globulin Reagent (can be ordered from Atlas Medical).
- White or transparent glass slide.

PRECAUTIONS

- The reagents are intended for in vitro diagnostic use only.
- The test is for well trained professional healthy user not for lay user.
- These reagents are derived from animal and human sources, thus, appropriate care must be taken in the use and disposal of these reagents, as there are no known test methods that can guarantee absence of infectious agents.
- Do not use reagents if it is turbid or contain particles as this may indicate reagent deterioration or contamination.
- Protective clothing should be worn when handling the reagents.
- **The reagents contain (0.1-0.2%) Sodium Azide and 0.02% sodium arseniate which is toxic and can be absorbed through the skin. When drained, the drains should be thoroughly flushed with water.**
- The reagents should be used as supplied and in accordance to the procedure mentioned below. Don't use beyond expiration date.
- Avoid cross contamination of reagents or specimens.
- Visible signs of microbial growth in any reagent may indicate degradation and the use of such reagent should be discontinued.

- Don't use these reagents if the label is not available or damaged.
- Do not use dark glass slide.
- Don't use the kit if damaged or the glass vials are broken or leaking and discard the contents immediately.
- Test materials and samples should be discarded properly in a biohazard container.
- Wash hands and the test table top with water and soap once the testing is done.
- Hemolysed blood sample should not be used for testing.
- The test should be performed at room temperature in a well lit area with very good visibility.
- Failure to follow the procedure in this package insert may give false results or safety hazard.
- Close the vial tightly after each test.
- The reagent is considered toxic, so don't drink or eat beside it.
- If spillage of reagent occurs clean with disinfectant (disinfectant used could be irritable so handle with care).

STORAGE CONDITIONS

- The reagents should be stored refrigerated between 2 - 8°C.
- Never Freeze or expose to elevated temperature.
- The reagent is stable until the expiry date stated on the product label. Do not use the reagents past the expiry date.

REAGENT PREPARATION

- The reagents are intended for use as supplied, no prior preparation or dilution of the reagent is required.
- All reagents should be brought to room temperature before use.

SPECIMEN COLLECTION AND PREPARATION

- Blood collected with or without anticoagulant (EDTA, Heparin or Citrate) can be used for Antigen typing.

Note: Blood collected without anticoagulant should be tested immediately.

- The specimens should be tested as soon as possible after collection. If testing is delayed, the specimens should be stored at 2- 8 °C. Sample must be retained to room temperature prior to analysis. (Testing should be carried out within five days of collections).
- Insure that there is no sign of hemolysis.
- At the time of the test, centrifuge the blood sample at 1200 RCF for 3 minutes.
- Blood collection is to be done with great care.

PROCEDURES

A. DIRECT TUBE METHOD AT ROOM TEMPERATURE

1. Prepare a 5% suspension of red blood cells in isotonic solution.
2. Using the vial dropper, transfer a drop (40±10µl) of each reagent into a separate and appropriately marked tube.
3. Add 50 µl of red blood cell suspension prepared in step 1.
4. Shake to homogenize the mixture, then centrifuge at 500g for **1 minute**.
5. Gently shake the tube in such a way to detach the cell pellet and macroscopically observe for any possible agglutination.
6. Read the reaction immediately.
7. For Anti-D tube, if the reaction is weak or negative, shake the tubes and incubate at 37°C for **15 minutes**.
8. Wash the red blood cells twice with isotonic saline solution (NaCl 0.9%) and discard the last washing liquid.
9. Add one drop (50µl) of the AHG reagent into the tube. Mix and centrifuge at 120g for **1 minute**.
10. Gently shake the tube in such a way to detach the cell pellet and macroscopically observe for any possible agglutination.
11. Read the reaction immediately.

B. ANTIGLOBULIN INDIRECT METHOD for ANTI-D

1. After immediately centrifuging and reading as above, if the reaction is weak or negative, shake the tubes and incubate at 37°C for 15 minutes.
2. Wash the red blood cells twice with isotonic saline solution (NaCl 0.9%) and discard the last washing liquid.
3. Add one drop (40 µl ± 10 µl) of ANTI-HUMAN GLOBULIN to the tube. Mix and centrifuge at 120 (g) for **1 minute**.
4. Gently shake the tube in such a way to detach the cell pellet and macroscopically observe for any possible agglutination.
5. Read the reaction immediately.

C. DIRECT SLIDE METHOD AT ROOM TEMPERATURE

1. Bring reagents and samples to room temperature (18-25°C).
2. Using the wax pen divide the slide into appropriate numbers of divisions.
3. Using the provided dropper, place one drop (40 µl ± 10 µl) of each reagent onto its correspondent division on the slide.
4. Add 25µl of the precipitated cells next to each drop of reagents.
5. Mix the reagent and the cells using a clean stirring stick over an area with a diameter of approximately 20-40mm.
6. Incubate the slide at room temperature (18-25°C) without stirring for **30 seconds**.
7. Hold the slide and gently rock the slide for **3 minutes** and observe macroscopically for any agglutination.
8. Read the reaction immediately.

READING THE RESULT
POSITIVE: If Agglutination appears.
NEGATIVE: If no agglutination is observed.
Use the below table to determine the blood group:

Result of each reaction				ABO Group
Anti-A monoclonal reagent	Anti-B monoclonal reagent	Anti-AB monoclonal reagent	Anti-D IgG/IgM blend reagent	
+	-	+	+	A+
+	-	+	-	A-
-	+	+	+	B+
-	+	+	-	B-
+	+	+	+	AB+
+	+	+	-	AB-
-	-	-	+	O+
-	-	-	-	O-

- STABILITY OF THE REACTIONS**
- ABO Blood Grouping Tube tests should be read immediately following centrifugation.
 - Slide tests should be interpreted within three minutes to avoid the possibility that a negative result may be incorrectly interpreted as positive due to drying of reagents.
 - Delay in reading and interpreting results may result in weekly positive or falsely negative reactions. Slide tests should be interpreted at the end of the three minutes.

- PROCEDURE LIMITATION**
1. False positive/ negative results may occur due to:
 - Contamination from test materials.
 - Improper storage, cells concentration, incubation time or temperature.
 - Improper or excessive centrifugation.
 - Deviation from the recommended technique.
 - Blood samples of weak A or B subgroups may give rise to false negative results or weak reactions when tested using slide test method. It is advisable to re-test weak subgroups using tube test method.
 2. Weaker reactions may be observed with stored blood than with fresh blood.
 3. ABO antigens are not fully developed at birth, weaker reactions may therefore occur with cord or neonatal red cells.
 4. ABO blood grouping interpretation on individuals greater than 6 months old should be confirmed by testing serum or plasma of the individual against group A and group B red cells (reverse grouping). If the results obtained with the serum do not correlate with the red cell test, further investigation is required.
 5. Return the kit to the agent if it does not function properly.
 6. Anti-D IgG/IgM blend Reagent tests conducted on particular weak-D phenotypes, while satisfactory, cannot ensure recognition of all weak variants, due to the variability of antigen patterns.

DIAGNOSTIC PERFORMANCE CHARACTERISTICS
The following tables compare the results in slide and tube techniques of 3 lots of Atlas Medical reagents and the results of a CE marked device.

Slide Technique				
Group A				
Positive with anti-A monoclonal reagent and anti-AB monoclonal reagent Negative with anti-B and Negative control				
CE marked device	Lot A	Lot B	Lot C	Compliance
232	232	232	232	100%
Tube Technique				
Group A				
Positive with anti-A monoclonal reagent and anti-AB monoclonal reagent Negative with anti-B and Negative control				
CE marked device	Lot A	Lot B	Lot C	Compliance
212	212	212	212	100%

Slide Technique				
Group B				
Positive with anti-B monoclonal reagent and anti-AB monoclonal reagent Negative with anti-A and Negative control				

CE marked device	Lot A	Lot B	Lot C	Compliance
61	61	61	61	100%
Tube Technique				
Group B				
Positive with anti-B monoclonal reagent and anti-AB monoclonal reagent Negative with anti-A and Negative control				
CE marked device	Lot A	Lot B	Lot C	Compliance
61	61	61	61	100%

Slide Technique				
Group O				
Negative with anti-A monoclonal reagent, Anti-B monoclonal reagent and anti-AB monoclonal reagent Negative with Negative control				
CE marked device	Lot A	Lot B	Lot C	Compliance
241	241	241	241	100%
Tube Technique				
Group O				
Negative with anti-A monoclonal reagent, Anti-B monoclonal reagent and anti-AB monoclonal reagent Negative with Negative control				
CE marked device	Lot A	Lot B	Lot C	Compliance
243	243	243	243	100%

Slide Technique				
Group AB				
Positive with anti-A monoclonal reagent, Anti-B monoclonal reagent and anti-AB monoclonal reagent Negative with Negative control				
CE marked device	Lot A	Lot B	Lot C	Compliance
33	33	33	33	100%
Tube Technique				
Group AB				
Positive with anti-A monoclonal reagent, Anti-B monoclonal reagent and anti-AB monoclonal reagent Negative with Negative control				
CE marked device	Lot A	Lot B	Lot C	Compliance
24	24	24	24	100%

No inversion in diagnosis has been shown: from a qualitative point of view we have observed 100% compliance in direct group testing in slide and tube techniques for determination of A, B, AB and O groups for the three lots of Atlas Medical.

QUALITY CONTROL
The reactivity of all blood grouping reagents should be confirmed by testing known positive and negative red blood cells on each day of use. To confirm the specificity and sensitivity, Blood grouping reagents should be tested with antigen-positive and antigen-negative red blood cells.

REFERENCES

1. BCSH Blood Transfusion Task Force. Guidelines for microplate techniques in liquid-phase blood grouping and antibody screening. Clin. Lab. Haem 1990: 12, 437-460.
2. Issitt P. D. Applied Blood Group Serology, 3rd ed. Miami: Montgomery Scientific, 1985.
3. Kholer G., Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity, 256, 495-497, 1975
4. Messeter L. et. al. Mouse monoclonal antibodies with anti-A, anti-B and anti-A,B specificities, some superior to human polyclonal ABO reagents, Vox Sang 46, 185-194, 1984
5. Race R.R. and Sanger R. Blood groups in man, 6th ed., Oxford: Blackwell Scientific, 1975.
6. Voak D. ET. al., Monoclonal anti-A and anti-B development as cost effective reagents. Med. Lab. Sci 39, 109-122. 1982.

7. Standards for Blood Banks d Transfusion Service. 11th Ed., Washington D.C., AABB 1984:25.

8. Widmann F.K.ed Technical Manual, 9th Ed., Wahington D.C.: AABB 1985:9.

















 Atlas Medical GmbH
Ludwig-Erhard-Ring 3
15827 Blankenfelde-Mahlow
Germany
Tel: +49 - 33708 – 3550 30
Email: Info@atlas-medical.com
Website: www.atlas-medical.com

PPI861A01
Rev.L (19.02.2022)



LIST OF VARIANTS:

Product Code	Product Name
8.02.00.0.0010	Anti-A Monoclonal Reagent (Titer: 1 /512), 10ml/vial, 1 vial/Carton Box
8.02.00.1.0100	Anti-A Monoclonal Reagent (Titer: 1 /512), 10ml/vial, 10 vials / Plastic Pack
8.02.00.1.0180	Anti-A Monoclonal Reagent (Titer: 1 /512), 10ml/vial, 18 vials / Carton Box
8.02.01.0.0010	Anti-B Monoclonal Reagent (Titer: 1 /512), 10ml/vial, / Carton Box
8.02.01.1.0100	Anti-B Monoclonal Reagent (Titer: 1 /512), 10ml/vial, 10 vials / Plastic Pack
8.02.01.1.0180	Anti-B Monoclonal Reagent (Titer: 1 /512), 10ml/vial, 18 vials / Carton Box
8.02.02.0.0010	Anti-AB Monoclonal Reagent (Titer: 1 /512), 10ml/vial, 1 vial/ Carton Box
8.02.02.1.0100	Anti-AB Monoclonal Reagent (Titer: 1 /512), 10ml/vial, 10 vials/Plastic Pack
8.02.02.1.0180	Anti-AB Monoclonal Reagent (Titer: 1 /512), 10ml/vial, 18 vials/Carton Box
8.02.03.0.0010	Anti-D IgG/IgM Blend Reagent (Titer: 1 /128), 10ml/vial, 1 vial/ Carton Box
8.02.03.1.0100	Anti-D IgG/IgM Blend Reagent (Titer: 1 /128), 10ml/vial, 10 vials / Plastic Pack
8.02.03.1.0180	Anti-D IgG/IgM Blend Reagent (Titer: 1 /128), 10ml/vial, 18 vials / Carton Box
8.02.04.0.0010	Anti-A Monoclonal Reagent (Titer: 1 /256), 10ml/vial, 1 Vial/Carton Box
8.02.04.0.0100	Anti-A Monoclonal Reagent (Titer: 1 /256), 10ml/vial, 10 vials / Plastic Pack
8.02.05.0.0010	Anti-B Monoclonal Reagent (Titer: 1 /256), 10ml/vial, 1vial/Carton Box
8.02.05.0.0100	Anti-B Monoclonal Reagent (Titer: 1 /256), 10ml/vial, 10 vials /Plastic Pack
8.02.05.6.0030	ABO Set (Anti-A (1/256), Anti-B (1 /256), Anti-D (1/64)),3x10ml / plastic Pack
8.02.05.7.0020	ABO Set: Anti-A (1/256), Anti-B (1 /256), 2x10ml /Plastic Pack
8.02.06.0.0010	Anti-AB Monoclonal Reagent (Titer: 1 /256), 10ml/vial, 1vial/Carton Box
8.02.06.1.0100	Anti-AB Monoclonal Reagent (Titer: 1 /256), 10ml/vial,10 vials /Plastic Pack
8.02.06.1.0180	Anti-AB Monoclonal Reagent (Titer: 1 /256), 10ml/vial,18 vials / Carton Box
8.02.07.0.0010	Anti-D IgG/IgM Blend Reagent (Titer: 1 /64), 10ml/vial, 1Vial/ Carton Box
8.02.07.1.0100	Anti-D IgG/IgM Blend Reagent (Titer: 1 /64), 10ml/vial, 10 vials / Plastic Pack
8.02.47.0.0030	ABO Set (Anti-A (1 /512), Anti-B (1 /512), Anti-D (1 /128)),3x10ml/Plastic Pack
8.02.47.1.0030	ABO Set (Anti-A (1 /256), Anti-B (1 /256), Anti-D (1 /64)), 3x10ml /Carton Box.
8.02.47.3.0030	ABO Set (Anti-A (1 /256), Anti-B (1 /256), Anti-D (1 /64)), 3x10ml /Plastic Pack
8.02.47.5.0030	ABO Set (Anti-A (1 /256), Anti-B (1 /256), Anti-D (1 /128)), 3x10ml/Plastic Pack
8.02.49.0.0040	ABO Set (Anti-A (1 /256), Anti-B (1 /256), Anti-AB (1 /256), Anti-D (1 /64)), 4x10ml/Carton Box
8.02.49.2.0040	ABO Set (Anti-A (1 /256), Anti-B (1 /256), Anti-AB (1 /256), Anti-D (1 /128)), 4 x 10ml, 4 vials/Plastic Pack
8.02.53.0.0040	ABO Set (Anti-A (1 /512), Anti-B (1 /512), Anti-AB (1 /512) Anti-D (1 /128)), 4x10ml/Plastic Pack
8.02.53.1.0040	ABO Set (Anti-A (1 /512), Anti-B (1 /512), Anti-AB (1 /512) Anti-D (1 /128)), 4x10ml, 4vials/Plastic Pack
8.02.70.0.0010	Anti-A monoclonal reagent , Titer (1/1024), 10 ml/vial, 1Vial/ Carton Box
8.02.71.0.0010	Anti-B Monoclonal reagent (Titer: 1 /1024) , 10 ml/vial ,1Vial/ Carton Box
8.02.72.0.0010	Anti-AB Monoclonal reagent (Titer: 1 /1024) , 10 ml/vial , 1Vial/ Carton Box
8.02.85.0.0010	Anti-D IgG/IgM Blend reagent (Titer 1 /256), 10ml/vial, 1Vial/ Carton Box

	Catalogue Number		Temperature limit
	In Vitro diagnostic medical device		Caution
	Contains sufficient for <n> tests and Relative size		Consult instructions for use (IFU)
	Batch code		Manufacturer
	Fragile, handle with care		Use-by date
	Manufacturer fax number		Do not use if package is damaged
	Manufacturer telephone number		Date of Manufacture
	Keep away from sunlight		Keep dry

ATLAS RHEUMATOID FACTOR (RF) LATEX KIT

latex slide test for the qualitative and semi-quantitative measurement of RF in human serum.

IVD For In-Vitro diagnostic and professional use only



Store at 2-8°C

INTENDED USE

A latex slide test for the qualitative and semi-quantitative measurement of RF in human serum.

INTRODUCTION

Rheumatoid factors (RF) are antibodies directed against antigenic sites in the Fc fragment of human and animal IgG. Their frequent occurrence in rheumatoid arthritis makes them useful for diagnosis and monitoring of the disease.

One method used for rheumatoid factor detection is based on the ability of rheumatoid arthritis sera to agglutinate sensitized sheep red cells, as observed by Waaler and Rose. A more sensitive reagent consisting of biologically inert latex beads coated with human gamma globulin was later described by Singer and Plotz. The RF kit is based on the principle of the latex agglutination assay of Singer and Plotz. The major advantage of this method is rapid performance (2 minute reaction time) and lack of heterophile antibody interference.

PRINCIPLE

The RF reagent is based on an immunological reaction between human IgG bound to biologically inert latex particles and rheumatoid factors in the test specimen. When serum containing rheumatoid factors is mixed with the latex reagent, visible agglutination occurs.

MATERIALS

MATERIALS PROVIDED

- RF Latex Reagent: Latex particles coated with human gamma-globulin, pH, 8.2. Preservative. Contains N, N-dimethylformamide.
- RF Positive Control Serum: Human serum with a RF concentration > 30 IU/mL. Preservative.

- RF Negative Control Serum: Animal serum. Preservative.
- Reaction Slide
- Stirring sticks

MATERIALS REQUIRED BUT NOT PROVIDED

- Timer
- Test Tubes (for dilution)
- Serological pipettes (for sample addition and for dilution)
- Rotator (optional)
- Glycine Buffer (20x): add one part to nineteen parts of distilled water before use.

PRECAUTIONS

- All reagents contain 0.1 % (w/v) sodium azide as a preservative.
- Reagents containing sodium azide may be combined with copper and lead plumbing to form highly explosive metal azides. Dispose of reagents by flushing with large amounts of water to prevent azide buildup.
- For In Vitro diagnostic use.
- Positive and negative controls prepared using human serum found negative for hepatitis B surface antigen (HBsAg) by FDA required test; however, handle controls as if potentially infectious.
- Accuracy of the test depends on the drop size of the latex reagent (40 µL). Use only the dropper supplied with latex and hold it perpendicularly when dispensing.
- Use a clean pipette tip and stirring stick for each specimen, and glass slides should be thoroughly rinsed with water and wiped with lint-free tissue after each use.
- Check reactivity of the reagent using the controls provided.

STORAGE AND STABILITY

- Reagents are stable until specified expiry date on bottle label when stored refrigerated (2-8°C).
- Do not freeze.
- The RF latex reagent, once shaken must be uniform without visible clumping. When stored refrigerated, a slight sedimentation may occur and should be considered normal.
- Do not use the latex reagent or controls if they become contaminated.

SPECIMEN COLLECTION AND STORAGE

- Use fresh serum collected by centrifuging clotted blood.
- If the test cannot be carried out on the same day, store the specimen for 7 days at 2-8°C and for 3 months at -20°C.
- As in all serological tests, hemolytic or contaminated serum must not be used.
- Do not use PLASMA.

PROCEDURE

Qualitative method

- Allow the reagents and samples to reach room temperature. The sensitivity of the test may be reduced at low temperatures.
- Place 50 µL of the sample and one drop of each Positive and Negative controls into separate circles on the slide test.
- Mix the RF-latex reagent rigorously or on a vortex mixer before using and add one drop (50 µL) next to the sample to be tested.
- Mix the drops with a stirrer, spreading them over the entire surface of the circle. Use different stirrers for each sample.
- Place the slide on a mechanical rotator at 80-100 r.p.m. for 2 minutes. False positive results could appear if the test is read later than two minutes.

Semi-quantitative method

- Make serial two fold dilutions of the sample in 9 g/L saline solution.
- Proceed for each dilution as in the qualitative method.

READING AND INTERPRETATION

Examine macroscopically the presence or absence of visible agglutination immediately after removing the slide from the rotator. The presence of agglutination indicates a RF concentration equal or greater than 8 IU/mL (Note 1). The titer, in the semi-quantitative method, is defined as the highest dilution showing a positive result.

CALCULATIONS

The approximate RF concentration in the patient sample is calculated as follows:

$$8 \times \text{RF Titer} = \text{IU/mL}$$

INTERFERENCES

NON INTERFERING SUBSTANCES:

- Hemoglobin (10g/dl)
- Bilirubin(20mg/dl)
- Lipemia(10g/dl)

Other substances may interfere.

QUALITY CONTROL

1. RF Positive and Negative Control should be included in each test batch.
2. Acceptable performance is indicated when a uniform milky suspension with no agglutination is observed with the RF Negative Control and agglutination with large aggregates is observed with the RF Positive Control.

PERFORMANCE CHARACTERISTICS

Analytical sensitivity

8(6-16) IU/ml, under the described assay conditions.

PROZONE EFFECT

No prozone effect was detected up to 1500 IU/ml.

DIAGNOSTIC SENSITIVITY

100%.

DIAGNOSTIC SPECIFICITY

100%.

The diagnostic sensitivity and specificity have been obtained using 118 samples compared with the same method of a computer.

LIMITATIONS

- Reaction time is critical. If reaction time exceeds 2 minutes, drying of the reaction mixture may cause false positive result.
- Freezing the RF Latex Reagent will result in spontaneous agglutination.
- Intensity of agglutination is not necessarily indicative of relative RF concentration; therefore, screening reactions should not be graded.
- Increased levels of RF may be found in some diseases other than rheumatoid arthritis such as infectious mononucleosis, sarcoidosis, lupus erythematosus, Sjogren's syndrome.
- Certain patients with rheumatoid arthritis will not have the RF present in their serum.

- The incidence of false positive results is about 3-5 %.Individuals suffering from infectious mononucleosis, hepatitis, syphilis as well as elderly people may give positive results.
- Diagnosis should not be solely based on the results of latex method but also should be complemented with a Waaler Rose test along with the clinical examination.

REFERENCE VALUES

Up to 8 IU/mL. Each laboratory should establish its own reference range.

NOTES

1. Results obtained with a latex method do not compare with those obtained with Waaler Rose test. Differences in the results between methods do not reflect differences in the ability to detect rheumatoid factors.

REFERENCES

1. Robert W Dorner et al. Clinica Chimica Acta 1987; 167: 1 – 21.
2. Frederick Wolfe et al. Arthritis and Rheumatism 1991; 34: 951- 960.
3. Robert H Shmerling et al. The American Journal of Medicine 1991; 91: 528 –534.
4. Adalbert F. Schubart et al. The New England Journal of Medicine 1959; 261: 363 – 368.
5. Charles M. Plotz 1956; American Journal of Medicine; 21:893 – 896.
6. Young DS. Effects of drugs on clinical laboratory test, 4th ed. AACC Press, 1995.














ATLAS MEDICAL

William James Hous Cowley Road,
Cambridge, CB4 0WX, UK.

Tel: +44 (0) 1223 858 910

Fax: +44 (0) 1223 858 524

PPI008A01, Rev H (17.06.2017)

	Catalogue Number		Store at
	For In-Vitro Diagnostic use		Caution
	Number of tests in the pack		Read product insert before use
	Lot (batch) number		Manufacturer
	Fragile, handle with care		Expiry date
	Manufacturer fax number		Do not use if package is damaged
	Manufacturer telephone number		

ANTISTREPTOLYSIN-O (ASO) LATEX SLIDE TEST

For the qualitative and quantitative measurement of antibodies to Antistreptolysin-O in human serum.

IVD For in -vitro diagnostic and professional use only



INTENDED USE

ATLAS ANTISTREPTOLYSIN-O (ASO) latex slide Test is used for the qualitative and quantitative measurement of antibodies to Antistreptolysin-O in human serum.

INTRODUCTION

The group A β -hemolytic streptococci produces various toxins that can act as antigens. One of these exotoxins streptolysin-O, was discovered by Todd in 1932.

A person infected with group A -hemolytic streptococci produces specific antibodies against these exotoxins, one of which is antistreptolysin-O. The quantity of this antibody in a patient's serum will establish the degree of infection due to the -hemolytic streptococcal.

The usual procedure for the determination of the antistreptolysin titer is based on the inhibitory effect that the patient's serum produces on the hemolytic power of a pre-titrated and reduced streptolysin-O. However, the antigen-antibody reaction occurs independently of the hemolytic activity of streptolysin-O. This property enables the establishment of a qualitative and quantitative test for the determination of the antistreptolysin-O by agglutination of latex particles on slide.

PRINCIPLE

ASO test method is based on an immunologic reaction between streptococcal exotoxins bound to biologically inert latex particles and streptococcal antibodies in the test sample. Visible agglutination occurs when increased antibody level, are present in the test specimen.

MATERIALS

MATERIALS PROVIDED

- ASO Latex Reagent: Latex particles coated with streptolysin O, pH, 8,2. Preservative
- ASO Positive Control(Red cap): Human serum with an ASO concentration > 200 IU/mL.Preservative
- ASO Negative Control (Blue cap) Animal serum. Preservative
- Reaction Slide.
- Stirring Sticks.

MATERIALS REQUIRED BUT NOT PROVIDED

- Timer.
- Test Tubes 12x75mm.
- Test Tube Rack.
- Serological pipettes.
- High intensity light.
- Saline Solution, 0.9% NaCL.

PRECAUTIONS

- All reagents contain 0.1% (w/v) sodium azide as a preservative. Store all reagents at 2-8°C. **DO NOT FREEZE.**
- Reagents containing sodium azide may be combined with copper and lead plumbing to form highly explosive metal azides. Dispose of reagents by flushing with large amounts of water to prevent azide build-up.
- For In Vitro diagnostic use.
- Positive and negative controls prepared using human serum found negative for hepatitis B surface antigen (HBsAg) and HIV-III by FDA required test; however, handle controls as if potentially infectious.

REAGENT STORAGE AND STABILITY

- Reagents are stable until specified expiry date on bottle label when stored refrigerated (2-8°C).
- **DO NOT FREEZE.**
- The ASO Latex Reagent, once shaken must be uniform without visible clumping. When stored refrigerated, a slight sedimentation may occur and should be considered normal.
- Do not use the latex reagent or controls if they become contaminated.

SPECIMEN COLLECTION AND STORAGE

- Use fresh serum collected by centrifuging clotted blood.
- If the test cannot be carried out on the same day, store the specimen for 7 days at 2-8°C and for 3 months at -20°C.

- For longer periods the sample must be frozen.
- As in all serological tests, hemolytic or contaminated serum must not be used.
- **DO NOT USE PLASMA.**

PROCEDURE

Qualitative method

1. Allow the reagents and samples to reach room temperature. The sensitivity of the test may be reduced at low temperatures.
2. Place 50 μ L of the sample and one drop of each Positive and Negative controls into separate circles on the slide test.
3. Mix the ASO-latex reagent vigorously or on a vortex mixer before using and add one drop (50 μ L) next to the sample to be tested.
4. Mix the drops with a stirrer, spreading them over the entire surface of the circle. Use different stirrers for each sample.
5. Place the slide on a mechanical rotator at 80-100 r.p.m. for 2 minutes. False positive results could appear if the test is read later than two minutes.

Semi-quantitative method

1. Make serial two fold dilutions of the sample in 9 g/L saline solution.
2. Proceed for each dilution as in the qualitative method.

QUALITY CONTROL

Positive and Negative Controls should be included in each test batch.

Acceptable performance is indicated when a uniform milky suspension with no agglutination is observed with the ASO Negative Control and agglutination with large aggregates is observed with the ASO Positive Control.

RESULTS

A.QUALITATIVE TEST:

A negative reaction is indicated by a uniform milky suspension with no agglutination as observed with the ASO Negative Control.

A positive reaction is indicated by any observable agglutination in the reaction mixture. The specimen reaction should be compared to the ASO Negative Control (Fig. 1).




Figure 1

B. QUANTITATIVE TEST

A positive reaction is indicated by any observable agglutination in the reaction mixture. Record the last dilution showing a positive reaction. Concentration of ASO can be determined by multiplying the last positive dilution factor of the sample with the concentration of the positive control (200 IU/ml).

The titer of the serum is the reciprocal of the highest dilution which exhibits a positive reaction.

IU/ml of sample = conc. of positive control (200) x specimen titer

<u>DILUTION</u>	<u>IU/ml</u>
1:1	200
1:2	400
1:4	800
1:8	1600
Etc.	

REFERENCE VALUES

Up to 200 IU/mL (adults) and 100 IU/mL (children < 5 years old)⁶. Each laboratory should establish its own reference range.

PERFORMANCE CHARACTERISTICS

Analytical sensitivity:

200 (±50) IU/ml.

PROZONE EFFECT

No prozone effect was detected up to 1500 IU/ml.

SENSITIVITY

98%.

SPECIFICITY

97%.

INTERFERENCES

NON INTERFERING SUBSTANCES:

- Hemoglobin (10g/dl)
- Bilirubin (20mg/dl)
- Lipemia (10g/dl)

Other substances may interfere

REFERENCES

1. Haffejee . Quarterly Journal of Medicine 1992. New series 84; 305: 641-658.
2. Ahmed Samir et al. Pediatric Annals 1992; 21: 835-842.
3. Spaun J et al. Bull Wld Hlth Org 1961; 24: 271-279.
4. The association of Clinical Pathologists 1961. Broadsheet 34.
5. Picard B et al. La Presse Medicale 1983; 23: 2-6.
6. Klein GC. Applied Microbiology 1971; 21: 999-1001.
7. Young DS. Effects of drugs on clinical laboratory test, 4th ed. AACC Press, 1995.



ATLAS Medical

William James House,














Cowley Road, Cambridge, CB4 4WX, UK

Tel: ++44 (0) 1223 858 910

Fax: ++44 (0) 1223 858 524

PPI003A01

Rev H (09.09.2017)

	Catalogue Number		Store at
	For In-Vitro Diagnostic use		Caution
	Number of tests in the pack		Read product insert before use
	Lot (batch) number		Manufacturer
	Fragile, handle with care		Expiry date
	Manufacturer fax number		Do not use if package is damaged
	Manufacturer telephone		

RPR SYPHILIS CARD TEST

A qualitative and Semi- quantitative rapid card test for the detection of Non-Treponema (reagin) in serum or plasma

IVD For in- vitro diagnostic use only

Store at 2 to 8 °C

INTENDED USE

For the qualitative and semi-quantitative detection of Non-Treponema in serum or plasma.

INTRODUCTION & PRINCIPLE

Besides other antibodies, *Treponema Pallidum* produces non-Treponemal antibodies (reagin) in syphilitic persons. These antibodies can be detected by RPR antigen. ATLAS RPR card test is a macroscopic screening test for the qualitative and Semi-quantitative detection of reagin antibodies in serum or plasma. The kit contains RPR antigen which is based on the easy to use VDRL carbon antigens. In the presence of the reagin, the antigen causes flocculation of the carbon particles, which appears as black clumps. The charcoal particles contained in the antigen suspension enhances the visual appearance of the coagglutination in positive samples.

MATERIALS

MATERIALS PROVIDED

- RPR carbon antigen reagent.
- Positive and negative controls.
- RPR test cards.
- Plastic sticks.
- Dispensing Dropper.

Note: This package insert is also used for individually packed reagent.

MATERIALS NEEDED BUT NOT PROVIDED

- Saline 0.9%.
- Rotator (100rpm).
- Accurate pipette to deliver 50 µl and.
- Timer.

SAMPLES

Fresh serum or plasma. Stable 7 days at 2-8°C or 3 months at -20°C. The samples with presence of fibrin should be centrifuged before testing. Do not use highly hemolized or lipemic samples.

PRECAUTIONS

- Always use a fresh pipette tip for every test.

STORAGE AND STABILITY

- The reagents in this kit should be stored in an upright position and refrigerated between 2 to 8°C. Never Freeze. Test cards need not to be refrigerated and can be kept at room temperature.
- Reagents should be brought to room temperature and mixed well to obtain a uniform suspension of carbon particles.

PREPARING THE SPECIMEN

- ATLAS RPR kit can be used with either unheated plasma or heated serum samples.
- Serum samples can stay stable for up to 5 days if stored at 2 to 8 °C.
- Plasma samples collected with EDTA can stay stable up to 24 hours if stored at 2 to 8 °C.

PROCEDURES

QUALITATIVE PROCEDURE

- **Mix well the RPR reagent before use.**
1. Bring reagents to room temperature.
 2. Dispense 50µl of sample onto a single circle on the test card.
 3. Repeat step 2 for the positive and negative controls.

4. Spread the sample of each test specimen over the entire test circle.
5. Mix the carbon antigen suspension well.
6. Dispense one drop (16µl) of the carbon antigen onto each test circle containing specimen. Do not mix the antigen with the sample.
7. Using the rotator, rotate the card at 100rpm for 8 minutes.
8. Read the results in good light immediately after 8 minutes.
9. Don't read the results after more than 8 minutes.

READING THE QUALITATIVE RESULTS

POSITIVE

- If large aggregates appear in the centre or the periphery of the test circle containing the sample, then the test should be read as positive (reactive)
- If the aggregates are visible, but weak or small, then the test should be read as weak positive (weakly reactive).
- If test is positive, then results should be confirmed by the quantitative procedure mentioned below.

NEGATIVE

If no aggregates appear and the specimen has smooth grey appearance (non-reactive)

SEMI-QUANTITATIVE PROCEDURE

- **Mix well the RPR reagent before use.**
1. Make serial two fold dilutions of the sample in 9 g/l saline solution.
 2. Dispense 50µl of 0.9% saline to test circles numbered 2 to 5. Saline should not be spread. Dispense 50 µl of specimen onto test circle 1.
 3. Dispense 50 µl of specimen onto test circle 2. Prepare serial two-fold dilutions by drawing the mixture up and down the pipette 5-6 times (avoid any bubble formation. Transfer 50 µl from circle 2 to 3, to 4 and to 5. Dispose 50 µl from circle 5 after mixing.

4. Starting from circle 5 and onto 4, 3, 2 and 1, mix and spread the serum over the entire area of each test circle.
5. Continue with steps 6-9 of the qualitative procedure.

READING THE SEMI-QUANTITATIVE RESULTS

The dilution of the circles are as follows:

Circle	1	2	3	4	5
Dilution	-	1:2	1:4	1:8	1:16

The titer of the sample is read as follows (P:Positive, N:Negative)

Positive 1:2	P	P	N	N	N
Positive 1:4	P	P	P	N	N
Positive 1:8	P	P	P	P	N
Positive 1:16	P	P	P	P	P

Positive and negative results are read as in the reading qualitative results procedure.

If the result in circle 5 is positive, then further dilution to 1:32, 1:64, 1:128 and 1:256 is required. Use steps 3 in semi-quantitative procedure and steps 6-9 in qualitative procedure to obtain the required dilutions.

**The titer , in the semi- quantitative method , is defined as the highest dilution showing a positive results.

PERFORMANCE CHARACTERISTICS

1. Analytical sensitivity: Accurate titer determination of the Reference Material, under the described assay conditions (see calibration).
2. Prozone effect: No prozone effect was detected up to titers $\geq 1/128$.
3. Diagnostic sensitivity: 100 %.
4. Diagnostic specificity: 100 %.

LIMITATION

- RPR carbon test is non-specific for syphilis.All Reactive samples should be retested with treponemic methods such as TPHA and FTA-Abs to confirm the results.

















- A Non Reactive result by itself does not exclude a diagnosis of syphilis. Clinical diagnosis should not be made on findings of a single test result, but should integrate both clinical and laboratory data.
- False positive results have been reported in diseases such as infectious mononucleosis, viral pneumonia, toxoplasmosis, pregnancy and autoimmune diseases.

REFERENCES

1. Falcone V.H., Stout G.W. and Moore M.B. Jr., PHR 79: 491-495, 1964.
2. Larsen S.A., *et. al.*, ata on file, Treponemal Research and Immunology lab, CDC.
3. McGrew B.E., Stout G.W., Falcon V.H., AM. J. Med. Techs., 34:634, 1969
4. Manual of Tests for Syphilis, PHS publication No.411, 1969.

 **ATLAS MEDICAL**
Ludwig-Erhard Ring 3
15827 Blankenfelde-Mahlow
Germany
Tel: +49 - 33708 – 3550 30
Email: Info@atlas-medical.com

PPI1511A01
Rev A (02.09.2019)

	Catalogue Number		Temperature limit
	In Vitro diagnostic medical device		Caution
	Contains sufficient for <n> tests and Relative size		Consult instructions for use (IFU)
	Batch code		Manufacturer
	Fragile, handle with care		Use-by date
	Manufacturer fax number		Do not use if package is damaged
	Manufacturer telephone number		Date of Manufacture
	Keep away from sunlight		Keep dry



浙江东方基因生物制品股份有限公司
Zhejiang Orient Gene Biotech Co.,LTD

STATEMENT

We, Zhejiang Orient Gene Biotech Co., Ltd , having a registered office at 3787#, East Yangguang Avenue, Dipu Street Anji 313300, Huzhou, Zhejiang, China assign SRL SANMEDICO having a registered office at A. Corobceanu street 7A, apt. 9, Chişinău MD-2012, Moldova, as non-exclusive authorized representative for Orient Gene Brand product in correspondence with the conditions of directive 98/79/EEC.

We declare that the company mentioned above is authorized to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova.

This Statement letter will be valid from Feb.21th,2023 to Feb.20th, 2024.

Zhejiang Orient Gene Biotech Co., Ltd

General Manager:

Date:2023/2/21



Handwritten signature in blue ink.

地址：浙江省湖州市安吉县递铺镇阳光大道东段 3787 号
Add: 3787#, East Yangguang Avenue, Dipu Street Anji 313300, Huzhou, Zhejiang, China
电话 Tel:+86-572-5226111 传真 Fax: +86-572-5226222 邮编 P.C.:313300



浙江东方基因生物制品股份有限公司
Zhejiang Orient Gene Biotech Co., LTD



CE-DOC-OG029
Version 4.0

EC Declaration of Conformity

In accordance with Directive 98/79/EC

Legal Manufacturer: *Zhejiang Orient Gene Biotech Co., Ltd*

Legal Manufacturer Address: *3787#, East Yangguang Avenue, Dipu Street,
Anji 313300, Huzhou, Zhejiang, China*

Declares, that the products
Product Name and Model(s)

Malaria P.f./P.v. Ag Rapid Test Cassette (Whole Blood)	GCMAL(pf/pv)-402a
--	-------------------

Classification: *Other*

Conformity assessment route: *Annex III (EC DECLARATION OF CONFORMITY)*

We, the Manufacturer, herewith declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In-Vitro Diagnostic Medical Devices.

We hereby explicitly appoint

EC Representative's Name: QARAD BV

EC Representative's Address: Ciplastraat 3, 2440 Geel, BELGIUM

to act as our European Authorized Representative as defined in the aforementioned Directive.

I, the undersigned, hereby declare that the medical devices specified above conform with the directive 98/79/EC on in vitro diagnostic medical devices and pertinent essential requirements

Date Signed: March 4, 2022

Name of authorized signatory: Joyce Pang
Position held in the company: Vice-President



浙江东方基因生物制品股份有限公司
Zhejiang Orient Gene Biotech Co., LTD



CE-DOC-OG039
Version 1.0

EC Declaration of Conformity

In accordance with Directive 98/79/EC

Legal Manufacturer: *Zhejiang Orient Gene Biotech Co., Ltd*

Legal Manufacturer Address: *3787#, East Yangguang Avenue, Dipu Street,
Anji 313300, Huzhou, Zhejiang, China*

Declares, that the products
Product Name and Model(s)

H. pylori Ag Rapid Test Strip (Feces)	GCHP-601a
H. pylori Ag Rapid Test Cassette (Feces)	GCHP-602a

Classification: *Other*
Conformity assessment route: *Annex III (EC DECLARATION OF CONFORMITY)*

We, the Manufacturer, herewith declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In-Vitro Diagnostic Medical Devices.

We hereby explicitly appoint

EC Representative's Name: *Shanghai International Holding Corp. GmbH (Europe)*

EC Representative's Address: *Eiffestrasse 80, 20537 Hamburg, Germany*

to act as our European Authorized Representative as defined in the aforementioned Directive.

I, the undersigned, hereby declare that the medical devices specified above conform with the directive 98/79/EC on in vitro diagnostic medical devices and pertinent essential requirements

Date Signed: November 28, 2017

Name of authorized signatory: *Joyce Pang*
Position held in the company: *Vice-President*



浙江东方基因生物制品股份有限公司
Zhejiang Orient Gene Biotech Co., LTD



CE-DOC-OG060
Version 1.0

EC Declaration of Conformity

In accordance with Directive 98/79/EC

Legal Manufacturer: *Zhejiang Orient Gene Biotech Co., Ltd*

Legal Manufacturer Address: *3787#, East Yangguang Avenue, Dipu Street,
Anji 313300, Huzhou, Zhejiang, China*

Declares, that the products
Product Name and Model(s)

Fecal Occult Blood Rapid Test Strip (Feces)	GEFOB-601b
Fecal Occult Blood Rapid Test Cassette (Feces)	GEFOB-602b

Classification: *Other*
Conformity assessment route: *Annex III (EC DECLARATION OF CONFORMITY)*

We, the Manufacturer, herewith declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In-Vitro Diagnostic Medical Devices.

We hereby explicitly appoint

EC Representative's Name: *Shanghai International Holding Corp. GmbH (Europe)*

EC Representative's Address: *Eiffestrasse 80, 20537 Hamburg, Germany*

to act as our European Authorized Representative as defined in the aforementioned Directive.

I, the undersigned, hereby declare that the medical devices specified above conform with the directive 98/79/EC on in vitro diagnostic medical devices and pertinent essential requirements

Date Signed: November 28, 2017

Name of authorized signatory: *Joyce Pang*
Position held in the company: *Vice-President*



浙江东方基因生物制品股份有限公司
Zhejiang Orient Gene Biotech Co., LTD



CE-DOC-OG285
Version 1.0

EC Declaration of Conformity

In accordance with Directive 98/79/EC

Legal Manufacturer: *Zhejiang Orient Gene Biotech Co., Ltd*

Legal Manufacturer Address: *3787#, East Yangguang Avenue, Dipu Street,
Anji 313300, Huzhou, Zhejiang, China*

Declares, that the products
Product Name and Model(s)

Giardia lamblia Antigen Rapid Test Cassette (Feces)	GCGIA-602a
---	------------

Classification: *Other*

Conformity assessment route: *Annex III (EC DECLARATION OF CONFORMITY)*

We, the Manufacturer, herewith declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In-Vitro Diagnostic Medical Devices.

We hereby explicitly appoint

EC Representative's Name: CMC Medical Devices & Drugs S.L

EC Representative's Address: C/Horacio Lengo N° 18, CP 29006, Málaga, Spain

to act as our European Authorized Representative as defined in the aforementioned Directive.

I, the undersigned, hereby declare that the medical devices specified above conform with the directive 98/79/EC on in vitro diagnostic medical devices and pertinent essential requirements

Date Signed: May 20, 2022

Name of authorized signatory: Joyce Pang
Position held in the company: Vice-President



Certificate

No. Q5 092305 0001 Rev. 01

Holder of Certificate: **Zhejiang Orient Gene Biotech Co., Ltd.**
3787#, East Yangguang Avenue, Dipu Street Anji
313300 Huzhou, Zhejiang
PEOPLE'S REPUBLIC OF CHINA

Certification Mark:



Scope of Certificate: **Design and Development, Production and Distribution of In Vitro Diagnostic Reagent and Instrument for the Detection of Drugs of Abuse, Fertility, Infectious Diseases, Oncology, Biochemistry, Cardiac Diseases, Allergic Disease based on Rapid Test, PCR and Liquid Biochip Method.**

The Certification Body of TÜV SÜD Product Service GmbH certifies that the company mentioned above has established and is maintaining a quality management system, which meets the requirements of the listed standard(s). All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: www.tuvsud.com/ps-cert?q=cert:Q5 092305 0001 Rev. 01

Report No.: SH2198802

Valid from: 2022-04-11

Valid until: 2024-03-16

Date, 2022-04-11

Christoph Dicks

Head of Certification/Notified Body

Certificate

No. Q5 092305 0001 Rev. 01

Applied Standard(s):

EN ISO 13485:2016
Medical devices - Quality management systems -
Requirements for regulatory purposes
(ISO 13485:2016)
DIN EN ISO 13485:2016

Facility(ies):

Zhejiang Orient Gene Biotech Co., Ltd.
3787#, East Yangguang Avenue, Dipu Street Anji, 313300
Huzhou, Zhejiang, PEOPLE'S REPUBLIC OF CHINA

See Scope of Certificate

H. pylori Ag Rapid Test Cassette (Feces)



INTENDED USE

H. pylori Ag Rapid Test Cassette (Feces) is a sandwich lateral flow chromatographic immunoassay for the qualitative detection of H. Pylori antigen in feces. It is for professional *in vitro* diagnostic use only.

INTRODUCTION

H. Pylori is associated with a variety of gastrointestinal diseases included non-ulcer dyspepsia, duodenal and gastric ulcer and active, chronic gastritis.^{1,2} The prevalence of H. pylori infection could exceed 90% in patients with signs and symptoms of gastrointestinal diseases. Recent studies indicate an association of H. Pylori infection with stomach cancer.³ H. Pylori colonizing in the gastrointestinal system elicits specific antibody responses^{4,5,6} which aids in the diagnosis of H. Pylori infection and in monitoring the prognosis of the treatment of H. Pylori related diseases. Antibiotics in combination with bismuth compounds have been shown to be effective in treating active H. Pylori infection. Successful eradication of H. pylori is associated with clinical improvement in patients with gastrointestinal diseases providing a further evidence.⁷

PRINCIPLE

H. pylori Ag Rapid Test Cassette (Feces) is a lateral flow chromatographic immunoassay based on the principle of the double antibody-sandwich technique. The test cassette consists of: 1) a burgundy colored conjugate pad containing H. Pylori antibodies conjugated with color particles (H. Pylori conjugates). 2) a nitrocellulose membrane strip containing a test band (T band) and a control band (C band). The T band is pre-coated with non-conjugated H. Pylori antibodies.

When an adequate volume of test specimen is dispensed into the sample well of the cassette, the specimen migrates by capillary action across the cassette. The antigen of H. Pylori if present in the specimen will bind to the H. Pylori antibodies conjugates. The immunocomplex is then captured on the membrane by the pre-coated H. Pylori antibodies, forming a burgundy colored T band, indicating a H. Pylori antigen positive test result. To serve as a procedural control, a colored line will always appear in the control line region indicating that proper volume of specimen has been added and membrane wicking has occurred. Otherwise, the test result is invalid and the specimen must be retested with another device.

PRODUCT CONTENTS

H. pylori Ag Rapid Test Cassette (Feces) containing anti- H. pylori antibodies particles and anti-H. pylori antibodies coated on the membrane.

MATERIALS SUPPLIED

20 Sealed pouches each containing a test cassette and a desiccant
20 Specimen collection tubes with extraction buffer, 2.0 mL
1 Package insert

MATERIAL REQUIRED BUT NOT PROVIDED

1. Clock or timer
2. Specimen collection containers.

STORAGE AND STABILITY

All reagents are ready to use as supplied. Store unused test device unopened at 2°C-30°C. If stored at 2°C-8°C, ensure that the test device is brought to room temperature before opening. The test is not stable out off the expiration date printed on the sealed pouch. Do not freeze the kit or expose the kit over 30°C.

WARNINGS AND PRECAUTIONS

1. For professional *in vitro* diagnostic use only.
2. Do not use it if the tube/pouch is damaged or broken.
3. Test is for single use only. Do not re- use under any circumstances.
4. Handle all specimens as if they contain infectious agents. Observe established standard procedure for proper disposal of specimens
5. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assay.
6. Humidity and temperature can adversely affect results

SPECIMEN COLLECTION

Collect sufficient quantity of feces (1-2 mL or 1-2 g) in a clean, dry specimen collection container to obtain maximum antigens (if present). Best results will be obtained if the assay is performed within 6 hours after collection. Specimen collected may be stored for 3 days at 2-8°C if not tested within 6 hours. For long term storage, specimens should be kept below -20°C.


To process fecal specimens:

• For Solid Specimens:

Unscrew the cap of the specimen collection tube, then randomly stab the specimen collection applicator into the fecal specimen in at least 3 different sites to collect approximately 50 mg of feces (equivalent to 1/4 of a pea). Do not scoop the fecal specimen.

• For Liquid Specimens:


Hold the dropper vertically, aspirate fecal specimens, and then transfer 2 drops (approximately 80 µL) into the specimen collection tube containing the dilution buffer. Screw on and tighten the cap onto the specimen collection tube, then shake the specimen collection tube vigorously to mix the specimen and the dilution buffer. Leave the tube alone for 2 minutes.



TEST PROCEDURE

1. Remove the test device from its foil pouch by tearing along the notch and use it as soon as possible.
2. Specimen collection. See also specimen collection.
3. Holding the sample collection device upright, carefully break off the tip of collection device.
4. Squeeze 2 drops (~80 µL) of the sample solution in the sample well of the cassette, as in the illustration.
5. Read the test results in 10 minutes. It is important that the background is clear before the result is read. Do not read results after 10 minutes. To avoid confusion, discard the test device after interpreting the result.

INTERPRETATION OF RESULTS



H. pylori Ag Rapid Test Cassette (Feces)

Positive: Two lines appear. One colored line should be in the control line region (C) and another apparent colored line should be in the test line region (T).

Negative: One colored line appears in the control line region(C). No line appears in the test line region (T).

Invalid: Control line fails to appear.

QUALITY CONTROL

A procedural control is included in the test. A colored line appearing in the control line region (C) is an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit; however, it is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

LIMITATIONS

1. The Assay Procedure and the Assay Result Interpretation must be followed closely when testing the presence of H. Pylori antigen in feces from individual subjects. Failure to follow the procedure may give inaccurate results.

2. H. pylori Ag Rapid Test Cassette (Feces) is limited to the qualitative detection of H. Pylori antigen in feces. The intensity of the test band does not have linear correlation with the antigen titer in the specimen.

3. A negative result for an individual subject indicates absence of detectable H. Pylori antigen. However, a negative test result does not preclude the possibility of exposure to or infection with H. Pylori.

4. A negative result can occur if the quantity of the H. Pylori antigen present in the specimen is below the detection limits of the assay, or the antigen that are detected are not present during the stage of disease in which a sample is collected.

5. The results obtained with this test should only be interpreted in conjunction with other diagnostic procedures and clinical findings.

PERFORMANCE CHARACTERISTICS

A study was performed with 165 patient feces samples including both symptomatic gastrointestinal disorders and samples from non-symptomatic patients and 100 normal feces samples.Comparison for all subjects with H. pylori Ag Rapid Test Cassette (Feces) and reference ELISA kit is showed in the following table:

Method		EIA		Total Results
H.P Test Cassette	Results	Positive	Negative	
	Positive	163	0	163
	Negative	2	100	102
Total Results		165	100	265

Relative sensitivity: 98.8%

Relative specificity: 100%

Accuracy:98.9%

REFERENCE

1. Marshall,B.J.et.al. Pyloric Campylobacter infection and gastroduodenal disease. Med. J. Australia.149:439-44, 1985.

2. Marshall,B.J.et.al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. Dec.1437-42,1988.

3. Megraud,F.et.al. Seroepidemiology of Campylobacter pylori infection in virious populations J.Clin.Microbiology. 27:1870-3,1989.

4. Soll,A.H. Pathogenesis of peptic ulcer and implications for therapy. New England J. Med.322:909-916,1990.

5. Parsonnet,J.et.al. Helicobacter pylori infection and the risk of gastric carcinoma. New England J.Med. 325:1127-31,1991.

6. Ansong,R. et.al. Evaluation of techniques for isolation, subcultivation and preservation of Helicobacter pylori. J.Clin.Micro. 29:51-53,1991.

7. Pronovost,A.P.et.al. Evaluation of a new immunodiagnostic assay for Helicobacter pylori antibody detection: Correlation with histopathological and microbiological results. J.Clin.Microbiol.32:46-50,1994.

INDEX OF SYMBOLS

	Consult instructions for use		Tests per kit		Authorized Representative
	For <i>in vitro</i> diagnostic use only		Use by		Do not reuse
	Store between 2~30°C		Lot Number		Catalog#



Zhejiang Orient Gene Biotech Co.,Ltd
Address: 3787#, East Yangguang Avenue, Dipu Street,
Anji 313300, Huzhou, Zhejiang, China.
TEL: +86-572-5226111 FAX: +86-572-5226222
Website: www.orientgene.com



Shanghai International Holding Corp. GmbH (Europe)
Add: Eiffestrasse 80, 20537 Hamburg, Germany



GCHP-602a

Revision Date: 2022-03-08
B20435-03

Malaria P.f./P.v. Ag Rapid Test Cassette (Whole Blood)



INTENDED USE

The Malaria P.f./P.v. Ag Rapid Test Cassette (Whole Blood) is a rapid lateral flow chromatographic immunoassay for the simultaneous detection and differentiation of Malaria P.falciparum specific histidine rich protein-2 (Pf HRP-II) and Malaria P.vivax specific lactate dehydrogenase (Pv-LDH) in human blood specimen as an aid in the diagnosis of Malaria infection. It is for *In-Vitro* Diagnostic use only.

INTRODUCTION

Malaria is a serious, sometimes fatal, parasitic disease characterized by fever, chills, and anemia and is caused by a parasite that is transmitted from one human to another by the bite of infected Anopheles mosquitoes. There are four kinds of malaria that can infect humans: Plasmodium falciparum, P. vivax, P. ovale, and P. malariae. In humans, the parasites (called sporozoites) migrate to the liver where they mature and release another form, the merozoites. The disease now occurs in more than 90 countries worldwide, and it is estimated that there are over 500 million clinical cases and 2.7 million malaria-caused deaths per year. At the present, malaria is diagnosed by looking for the parasites in a drop of blood. Blood will be put onto a microscope slide and stained so that the parasites will be visible under a microscope.

PRINCIPLE

The Malaria P.f./P.v. Ag Rapid Test Cassette (Whole Blood) contains a membrane, which is precoated with mouse monoclonal antibodies specific to HRP-II of P. falciparum on test line Pf region and with mouse monoclonal antibodies specific to lactate dehydrogenase of P. vivax species on test line Pv region respectively. Conjugate pad is dispensed with monoclonal antibodies conjugated to colloidal gold, which are specific to P. falciparum histidine rich protein-2 (Pf HRP-II) and specific to the lactate dehydrogenase of P. vivax.

During the assay, an adequate volume of the blood specimen is dispensed into the sample well (S) of the test cassette, a lysis buffer is added to the buffer well (B). The buffer contains a detergent that lyses the red blood cells and releases various antigens, which migrate by capillary action across the strip held in the cassette. Pv-LDH if presents in the specimen will bind to the Pv-LDH-gold conjugates. The immunocomplex is then captured on the membrane by the pre-coated anti-Pv-LDH antibody, forming a burgundy colored Pv band, indicating a Pv positive test result.

Alternatively, pHRP-II if presents in the specimen will bind to the pHRP-II-gold conjugates. The immunocomplex is then captured on the membrane by the pre-coated anti-pHRP-II antibodies, forming a burgundy colored Pf band, indicating a Pf positive test result.

Absence of any T bands suggests a negative result. The test contains an internal control (C band) which should exhibit a burgundy colored band of the immunocomplex of goat anti- mouse IgG I mouse IgG (anti-Pv-LDH and anti-pHRP-II)-gold conjugates regardless of the color development on any of the T bands. Otherwise, the test result is invalid and the specimen must be retested with another device.

MATERIALS SUPPLIED

25 Sealed pouches each containing a test cassette, a dropper and a desiccant
1 Buffer, 7.0 mL
1 Package insert

MATERIAL REQUIRED BUT NOT PROVIDED

1. Clock or timer
2. Collection by venipuncture: collection tube (containing EDTA, citrate or heparin)
3. Collection using a lancet: sterile lancet

STORAGE AND STABILITY

All reagents are ready to use as supplied. Store unused test device unopened, preferably at 2°C-30°C. Do not expose the kit over 30°C. Do not freeze the kit. Ensure that the test device is brought to room temperature before opening. The test device is stable through the expiration date printed on the sealed pouch if it is stored at 2°C-30°C.

WARNINGS AND PRECAUTIONS

1. For professional *in vitro* diagnostic use only. Do not use after expiration date.
2. The instruction must be followed exactly to get accurate results. Failure to follow the insert gives inaccurate test results.
3. Do not eat, drink or smoke in the area where the specimens or kits are handled.
4. Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout testing and follow the standard procedures for proper disposal of specimens.

5. Hemolized blood may be used for the testing, but do not take precipitants.
6. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are being tested.
7. Humidity and temperature can adversely affect results.
8. Do not perform the test in a room with strong air flow, ie. an electric fan or strong airconditioning.

SPECIMEN COLLECTION

Collection by venipuncture:

- 1) Collect whole blood into a collection tube (containing EDTA, citrate or heparin) by venipuncture.
- 2) If specimens are not immediately tested, they should be refrigerated at 2-8°C. For storage periods greater than three days, freezing is recommended. They should be brought to room temperature prior to use. Using the specimen after long-term storage of more than three days can cause non-specific reaction.
- 3) When stored at 2-8°C, the whole blood sample should be used within three days.

Collection using a lancet:

- 1) Clean the area to be lanced with an alcohol swab.
- 2) Squeeze the end of the fingertip and pierce with a sterile lancet.
- 3) Wipe away the first drop of blood with sterile gauze or cotton.
- 4) Using the dropper provided, while gently squeezing the tube, immerse the open end in the blood drop and then gently release the pressure to draw blood into the dropper.

TEST PROCEDURE

Allow the test device, specimen, buffer, and/or controls to equilibrate to room temperature (15-30°C) prior to testing.


1. Remove the test cassette from the foil pouch and use it as soon as possible. Best results will be obtained if the assay is performed within one hour.
2. Place the test cassette on a clean and level surface. Be sure to label the device with specimen's ID number.
3. With a 5 µL mini plastic dropper provided, draw whole blood specimen to exceed the specimen line as showed in the following image and then transfer drawn whole blood into the sample well (S). Then add 3 drops (about 120 µL) of Lysis Buffer to the buffer well (B) immediately.

Note: Practice a few times prior to testing if you are not familiar with the mini dropper. For better precision, transfer specimen by pipette capable to deliver 5 µL of volume.

4. Set up timer.

If preferred, after 5 minutes of adding specimen and buffer, you may add one more drop of Lysis Buffer to help the background become clearer.

5. Results can be read in 20 to 30 minutes. It may take more than 20 minutes to have the background become clearer. Don't read results after 30 minutes. To avoid confusion, discard the test cassette after interpreting the result.



Malaria P.f./P.v. Ag Rapid Test Cassette (Whole Blood)

INTERPRETATION OF RESULTS

(Please refer to the illustration above)

POSITIVE:

P.f Positive: One line appears in the control region, and one line appears in P.f. line region.

P.v Positive: One line appears in the control region and one line appears in Pv line region.

P.f and P.v Positive: One line appears in the control region, one line appears in Pv line region and one line appears in P.f. line region.

NEGATIVE: Only one colored line appears in the control region.

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test device. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

QUALITY CONTROL

Internal procedural controls are included in the test. A colored line appearing in the control region (C) is an internal procedural control. It confirms sufficient specimen volume and correct procedural technique. Control standards are not supplied with this kit; however, it is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

LIMITATIONS

1. The Malaria P.f./P.v. Ag Rapid Test Cassette (Whole Blood) is for *in vitro* diagnostic use only. This test should be used for the detection of P.f and P.v antigens in whole blood specimens only. Neither the quantitative value nor the rate of increase in P.f and P.v concentration can be determined by this qualitative test.
2. The Malaria P.f./P.v. Ag Rapid Test Cassette (Whole Blood) will only indicate the presence of antigens of P.f and / or P.v in the specimen and should not be used as the sole criterion for the diagnosis of malaria infection.
3. As known relevant interference, haemolytic samples, rheumatoid factors-contained samples and lipaemic, icteric samples can lead to impair the test results.
4. The test is limited to the detection of antigen to Malaria Plasmodium sp. Although the test is very accurate in detecting HRP-II specific to P.f or pLDH specific to P.v, a low incidence of false results can occur. Other clinically available tests are required if questionable results are obtained.
5. If the test result is negative and clinical symptoms persist, additional testing using other clinical methods is recommended. A negative result does not at any time preclude the possibility of malaria infection.
6. As with all diagnostic tests, a definitive clinical diagnosis should not be based on the results of a single test, but should only be made by the physician after all clinical and laboratory findings have been evaluated.

PERFORMANCE CHARACTERISTICS

1. Clinical Performance for P.f Ag test:

A total of 352 samples from susceptible subjects were tested by the Malaria P.f./P.v. Ag Rapid Test Cassette (Whole Blood) and by thick blood smear test.

Method		Smear Test		Total Results
Malaria Pf/Pv Ag Rapid Test	Results	Positive	Negative	
	Positive	50	4	54
	Negative	0	298	298
Total Results		50	302	352

Relative Sensitivity: 100%

Relative Specificity: 98.7%

Overall Agreement: 98.9%

2. Clinical Performance for P.v Ag test:

A total of 289 samples from susceptible subjects were tested by the Malaria P.f./P.v. Ag Rapid Test Cassette (Whole Blood) and by thick blood smear test.

Method		Smear Test		Total Results
Malaria Pf/Pv Ag Rapid Test	Results	Positive	Negative	
	Positive	63	3	66
	Negative	0	223	223
Total Results		63	226	289

Relative Sensitivity: 100%

Relative Specificity: 98.7%

Overall Agreement: 99.0%

3. Precision: Within-run and between-run have been determined by the testing 10 replicates of four specimens: a negative, a low positive, a medium positive and a strong positive. All values were correctly identified 100% of the time.

4. Interference: To evaluate the interference of Malaria P.f./P.v. Ag Rapid Test Cassette (Whole Blood) with known relevant interfering specimens, the haemolytic samples, rheumatoid factors-contained samples and lipaemic, icteric samples were investigated. In these studies, those specimens did not interfere with the Malaria P.f./P.v. Ag Rapid Test Cassette (Whole Blood).

REFERENCE

1. Leonard K. Basco, Frederique Marquet, Michael M. Makler, and Jacques Le Bras.: Plasmodium falciparum and Plasmodium vivax: Lactate Dehydrogenase Activity and its Application for *in vitro* Drug Susceptibility Assay. Experimental Parasitology 80, 260-271 (1995)
2. David L. Vander Jagt, Lucy A. Hunsaker and John E. Heidrich : Partial Purification and Characterization of Lactate Dehydrogenase from Plasmodium falciparum. Molecular and Biochemical Parasitology, 4 (1981) 255-264
3. David J. Bzik, Barbara A. Fox and Kenneth Gonyer : Expression of Plasmodium falciparum lactate dehydrogenase in Escherichia coli Molecular and Biochemical Parasitology, 59(1993) 155-166
4. Histidine-Rich Protein II: a Novel Approach to Malaria Drug Sensitivity Testing ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2002, p. 1658©1664 Vol. 46, No. 6

INDEX OF SYMBOLS

	Consult instructions for use		Tests per kit		Authorized Representative
	For <i>in vitro</i> diagnostic use only		Use by		Do not reuse
	Store between 2~30°C		Lot Number		Catalog#

 Zhejiang Orient Gene Biotech Co., Ltd
Address: 3787#, East Yangguang Avenue, Dipu Street,
Anji 313300, Huzhou, Zhejiang, China
Tel: +86-572-5226111 Fax: +86-572-5226222
Website: www.orientgene.com

 QARAD BV
Cipalstraat 3, 2440 Geel BELGIUM

 GCMAL(pf/pv)-402a

Revision Date: 2022-09-26
B20885-03